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This dissertation studies the adverse financial implications of "longevity risk" and 
"mortality risk", which have attracted the growing attention of insurance companies, 
annuity providers, pension funds, public policy decision-makers, and investment banks. 
Securitization of longevity/mortality risk provides insurers and pension funds an effective, 
low-cost approach to transferring the longevity/mortality risk from their balance sheets to 
capital markets. The modeling and forecasting of the mortality rate is the key point in 
pricing mortality-linked securities that facilitates the emergence of liquid markets. 
 
First, this dissertation introduces the discrete models proposed in previous literature. The 
models include: the Lee-Carter Model, the Renshaw Haberman Model, The Currie Model, 
the Cairns-Blake-Dowd (CBD) Model, the Cox-Lin-Wang (CLW) Model and the 
Chen-Cox Model. The different models have captured different features of the historical 
mortality time series and each one has their own advantages. 
vi 
 
 
Second, this dissertation introduces a stochastic diffusion model with a double 
exponential jump diffusion (DEJD) process for mortality time-series and is the first to 
capture both asymmetric jump features and cohort effect as the underlying reasons for the 
mortality trends. The DEJD model has the advantage of easy calibration and 
mathematical tractability. The form of the DEJD model is neat, concise and practical. The 
DEJD model fits the actual data better than previous stochastic models with or without 
jumps. To apply the model, the implied risk premium is calculated based on the Swiss Re 
mortality bond price. The DEJD model is the first to provide a closed-form solution to 
price the q-forward, which is the standard financial derivative product contingent on the 
LifeMetrics index for hedging longevity or mortality risk. 
 
Finally, the DEJD model is applied in modeling and pricing of life settlement products. A 
life settlement is a financial transaction in which the owner of a life insurance policy sells 
an unneeded policy to a third party for more than its cash value and less than its face 
value. The value of the life settlement product is the expected discounted value of the 
benefit discounted from the time of death. Since the discount function is convex, it 
follows by Jensen’s Inequality that the expected value of the function of the discounted 
benefit till random time of death is always greater than the benefit discounted by the 
expected time of death. So, the pricing method based on only the life expectancy has the 
negative bias for pricing the life settlement products. I apply the DEJD mortality model 
using the Whole Life Time Distribution Dynamic Pricing (WLTDDP) method. The 
WLTDDP method generates a complete life table with the whole distribution of life times 
instead of using only the expected life time (life expectancy). When a life settlement 
underwriter’s gives an expected life time for the insured, information theory can be used 
to adjust the DEJD mortality table to obtain a distribution that is consistent with the 
underwriter projected life expectancy that is as close as possible to the DEJD mortality 
model. The WLTDDP method, incorporating the underwriter information, provides a 
more accurate projection and evaluation for the life settlement products. Another 
advantage of WLTDDP is that it incorporates the effect of dynamic longevity risk 
changes by using an original life table generated from the DEJD mortality model table. 
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Chapter 1 Introduction to Longevity Risk 
1.1 BACKGROUND 
The adverse financial implications of "longevity risk" and "mortality risk" have 
attracted the growing attention of insurance companies, annuity providers, pension funds, 
public policy decision-makers, and investment banks. Longevity risk denotes the adverse 
financial consequences that ensue when an individual or group live longer than expected 
(i.e., their mortality rate is lower than what was expected at the time that the financial 
balancing of assets, set aside for future consumption or future payments, was made). 
Similarly, mortality risk describes the adverse financial consequences that ensue when an 
individual or group live a shorter time than expected (their mortality rate is higher than 
expected in the premium/benefit balancing equation). The International Actuarial 
Association defines four components of longevity/mortality risk: level, trend, volatility, 
and catastrophe. The four components can be categorized into two groups, systematic risk 
and specific risk (Crawford, et al. 2008). Systematic risk is defined as the 
underestimation or overestimation of the base assumption of mortality rates, including the 
level component and the trend component. Specific risk is defined as the volatility around 
the base assumption, including the volatility component and the catastrophe component. 
According to the Law of Large Numbers specific risks can be reduced by diversifying 
with a large pool of lives; however, systematic risk cannot be reduced by diversification. 
Clearly life insurers are interested in mortality risk because they have to pay death 
claims earlier than expected, resulting in an unbalanced loss of capital. Annuity providers, 
defined benefit pension plans and social insurance programs such as Social Security are 
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interested in longevity risk because they have to make financial payments for longer than 
was originally reserved. In addition to having substantial pension obligations such as 
social security programs, governments act as residual risk bearers of last resort and are 
becoming increasingly concerned with the financial consequences of citizens outliving 
their resources. 
The life insurance industry, as well as the annuity and pension industries, 
functioned reasonably for many decades, according to actuarial estimated projections. 
These plain vanilla products used standard mortality tables and conservative interest rates. 
However, situations are changing, and insurers, reinsurers, pension funds, and 
governmental life security schemes (e.g., social insurance) are changing as well. 
Illustrative of this on the life (mortality) side is the quote by Richard M. Todd and Neil 
Wallace in the 1992 Federal Reserve Board-Minneapolis Quarterly Review, "In 1980 the 
life insurance industry was 150 years old. In 1990 ... [it] was 10 years old." Increased 
competition by capital markets, increasingly sophisticated financial life insurance 
products, mutual funds, and new derivative instruments are re-sculpturing the landscape 
related to the transfer of certain risks in life insurance. Risks can now be transferred using 
capital markets and are not restricted to just reinsurance market risk transfer. A similar 
statement could be made in today's environment concerning the status of the 
annuity/pension/longevity risk market.1 It is currently undergoing rapid changes caused 
                                                 
1 It is interesting to note that annuity market sophistication has progressed substantially since the 
government of William III of England (November 4, 1650 --March 8, 1702) offered annuities of 14% 
regardless of whether the annuitant was 30 or 70 years of age (Pearson 1978, p. 134). Indeed, the mindset 
behind this was that one's death was considered to be an "act of God" which occurred whenever the all 
powerful God dictated that one's time had come. There was no room for "chance" in this contract. Death 
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by regulatory pressures, financial innovations, medical advances, pandemic threats, and 
capital market pressures on firms and governments having substantial pension obligations. 
The pressure on Pay-As-You-Go social security systems is severe because of the 
imminent retirement of the baby boom generation, followed by a baby bust generation. 
The next generation is unable to pick up the needed financial costs associated with 
longevity. A misestimation of costs incurred by using a life table that does not incorporate 
longevity changes can also create financial pressure for defined benefit pension plans of 
private enterprises or annuity providers. 
Sources of pressure on longevity risk sensitive entities come from several arenas 
including advances in medicine, nutrition, and sanitation. In the last several decades, life 
expectancy in the developed countries has, on average, been increasing by approximately 
1.2 months every year. Globally, life expectancy at birth has increased by 4.5 months per 
year on average over the second half of the 20th century (Gutterman, England, Parikh, 
and Pokorski, 2002). 
Substantial improvements in longevity during the 20th century have posed 
longevity risk management challenges to pension funds and other entities that originally 
reserved for expected future costs using what would now be considered incorrectly 
diminished mortality rates (older mortality tables). A 2006 study of the companies in the 
U.K.'s FTSE100 index found that many companies had based their estimates of pension 
                                                                                                                                                 
was deterministic and only appeared random to humans because people were "ignorant of God's will"!The 
development of rigorous probability theory by Fermat and Pascal (1654) and its subsequent application in 
1693 by Edmund Halley (of Halley's comet fame) to create the first mortality table (including an annuity 
pricing example) revolutionized the annuity and life insurance market then, just as the developments in the 
studies of the capital markets have revolutionized the insurance industry in more modern times. 
 
 4 
liabilities on mortality tables which underestimated expected lifetimes by not recognizing 
improving longevity, and by not recognizing this underestimation of expected lifetimes 
would cause the aggregate deficit in pension reserves to more than double from £46 
billion to £100 billion (Pension Capital Strategies and Jardine Lloyd Thompson, 2006). In 
2010 alone, improved life expectancy added £5 billion to corporate pension obligations in 
the U.K. (Reuters, 2010). In the U.S., the Internal Revenue Service (IRS) has recently 
established new mortality assumptions for pension contributions, which according to 
Watson Wyatt insurance consulting firm, will increase pension liabilities by 5-10%, 
(Halonen, 2007). Mercer Human Resource Consulting has calculated that the use of up-
to-date mortality tables would increase the cost of providing a pension to a male born in 
1950 by 8%, Mercer (2006). Additionally, U.S. insurance regulation ignores changes in 
longevity risk (or mortality risk) in the current Risk Based Capital (RBC) formula for 
calculation of insurance risk. An imbalanced approach to assets and liabilities can affect 
the capital structure of insurance or reinsurance companies and increase their default risk. 
The insurance or reinsurance companies that ignore longevity risk in designing and 
pricing their insurance products, including their annuity and life insurance products, run a 
substantial risk of underestimating their ultimate product costs which can cause a liability 
payment shortage for certain products. 
Interaction of the insurance industry with the capital markets (Cummins, 2005) 
provides a vehicle for mitigating the above mentioned mortality/longevity risk, namely, 
through financial securitization of life and pension products (c.f., MacMinn, Brockett, 
and Blake, 2006). Securitization provides an approach to transferring non-diversifiable 
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mortality/longevity risk from the insurer's or pension's balance sheet to the capital market. 
Moreover, this capital market transfer may provide an attractive alternative to reinsurance 
because of the size of the liabilities. According to Cummins and Trainer (2009, p.475), 
"… the traditional reinsurance model begins to break down when risks are correlated, add 
significantly to the reinsurer asymmetry risk, and are large relative to the reinsurer's 
equity capital. The cost of capital is also increased by informational asymmetries between 
reinsurers and capital market and by agency costs and other market frictional costs. 
Under these conditions, the price of reinsurance may be prohibitively high, and the 
supply of coverage may be restricted." Longevity risk for pension plans or annuity 
providers is an example of such correlated risk (mortality improvements or pandemics 
affect many individuals in the insurer's book of business). In these circumstances 
securitization can help address the inefficiencies in the reinsurance market such as 
correlation between risks and counterparty credit risk in the case of large or catastrophic 
risk (cf., Cummins and Trainer, 2009). Moreover, the capital markets are also 
significantly larger in capacity than are the reinsurance markets, so spreading the risk 
among the capital market participants can reduce insolvency risk. Additionally, since the 
securitized insurance products tend to be uncorrelated (or lowly correlated) with other 
assets in the economy, these securitized mortality/longevity risk transfer instruments can 
be attractive to investors wishing to diversify their own risks by putting an essentially 
zero beta asset into their portfolios. Securitization also enhances the risk capacity of the 
insurance industry, as illustrated by the catastrophe (CAT) mortality bond and other 
similar derivatives, whose payment depends on the underlying loss indices and the 
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catastrophic mortality event. On the insurance policy holder side, many investment banks 
have recently been involved in life-settlement securitization. Investment banks purchased 
hundreds of thousands of life insurance policies and repackaged them into bonds, then 
sold bonds to investors such as pension funds. The high return of the life settlement is 
attractive to the investors. The expected rate of return to an investor in such a bond 
depends on the projected life expectancy of the members in the pool of life insurance 
policies (Modu 2009). 
Capital market solutions to longevity risk problems have grown increasingly 
important in recent years, both in academic research and in the Life Markets, the capital 
markets that trade longevity-linked assets and liabilities. Capital markets can, in principle, 
provide vehicles to hedge longevity risk effectively. Many new investment products have 
been created both by the insurance/reinsurance industry and by the capital markets. 
Mortality catastrophe bonds are an example of a successful insurance-linked security. 
Some new innovative capital market solutions for transferring longevity risk include 
longevity (or survivor) bonds, longevity (or survivor) swaps and mortality (or q-) forward 
contracts. 
1.2 TREND AND OUTLOOK OF RETIREMENT MARKET 
A range of previous research has reached the same conclusion: people are living 
longer than they ever have in the past, or the life expectancy of people has obviously 
increased. Significant medical progress, improved living standards, healthier lifestyles 
that include organic food, the absence of global wars and pandemic influenza crises are 
some of the main environmental reasons for the increase in life expectancy. 
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In the United States, the number of centenarians (individuals over the age of 100) 
has increased from 15,000 in 1980 to roughly 72,000 in 2000. The Social Security 
Advisory Board using U.S. Census Bureau data, predicts the number of centenarians will 
increase to 4.2 million by 2050, which is approximately 1% of the projected total 
population (Scotti and Effenberger, 2007).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
The life expectancy at birth for people living in several countries that are the 
members of the Organization for Economic Cooperation and Development (OECD) is 
shown in Figure 1. In the study of UN World Population prospects, the projections of 
Japanese lives from 1950 through 2050 indicate that on average life expectancy at birth 
will increase at a rate of approximately 3.2 months per year for females and 2.7 months 
per year for males (Scotti and Effenberger, 2007).  
Figure1 Life Expectancy at Birth in Different Regions 
 
In the next few decades, most OECD countries are expected to experience what 
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has been called "the demographic time bomb." It is unambiguous that there is a higher 
life expectancy and a lower birth rate in these countries. The OECD includes Japan, 
South Korea, etc., which also exhibit very low birth rates and increasing longevity which 
implies an inversion of the standard age distributions. In 2050, 27% of the European 
population is expected to be older than 65 years (versus 16% in 2005), and about 10% is 
projected to be older than 85 (versus 3.5% in 2005) (Scotti and Effenberger, 2007). 
Figure 2 Old-Age Dependency Ratio in Selected Countries 
 
Figure 2 illustrates the old-age dependency ratio (the ratio of the population aged 
65 and older to that aged 15 to 64). While today the ratio is around 25% in a typical 
developed country, in 2050 it is estimated to rise to 70% in countries such as Japan and 
Italy (Scotti and Effenberger, 2007). Traditionally the over 65 population is considered to 
be the retired population who are supported by (dependent on) the "working" population 
aged 15-64. A ratio of 25% means there are four workers supporting (via taxes and other 
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manners) each person over 65. A ratio of 70% means each person over 65 will have to be 
supported by only approximately 1.4 workers, a burden almost three times as great as that 
today. 
While mortality improvement trends can be observed in the entire population, the 
specific amount of mortality improvement is different for different age groups and 
depends on when the individual was born. (See Figure 3) The term "cohort effect" 
describes anomalies in observed mortality improvement for individuals born during a 
specific period of time or having specific characteristics in common.  Figure 3 shows 
the longevity in women in various countries and shows that different countries exhibit 
different effects. 
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Figure 3 Female Life Expectancy 
 
In the next section, we shall review the capital market instruments that are 
proposed to transfer longevity and mortality risk. 
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Chapter 2 The Longevity Risk Models and Products 
2.1 MORTALITY RATE MODELS FOR USE IN CAPITAL MARKET HEDGING 
The capital market provides a new way to hedge the longevity risk or mortality 
risk for pension funds, annuity providers and insurance companies. The pricing of the 
mortality and longevity risk contingent financial instruments depends on the estimation 
and projection of the mortality rate in a cohort of lives. This can be cumulative (as in the 
Swiss Re Mortality Catastrophe Bond) or for a specified birth cohort at a specific age. 
For any of these there is a need to develop a theoretical model of mortality. We shall 
discuss several of the currently used mortality models and examine their strengths. 
2.2 DISCRETE TIME MODELS 
2.2.1 Lee-Carter Model. 
Lee and Carter (1992) proposed the first stochastic model for mortality rate. 
                      
                
Here x represents the age of the individual, t represents time (date), and      represents 
the mortality rate of a person aged x in year t.    represents the age group shift effect, 
exp(  ) is the general shape across the age of the mortality schedule, and    represents 
the age group's reaction effect to the mortality time-series   . The    profile tells us 
which group of mortality rates declines rapidly and which group declines slowly to 
changes in   , and      captures the age group's residual effect not reflected in the 
model. m is the drift, σ is the variance for the mortality time-series   , and      follows 
the standard normal distribution. 
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There is an identification problem in this parameterization. Lee and Carter 
introduce the normalizing conditions: 
     
 
 
         
 
 
To estimate the parameters in the model, these constraints resolve an identification 
problem that would occur in the general model if the constraints were not imposed. The 
values of age-specific parameters   ,   , and mortality time-series    can be generated 
througth the Singular Value Decomposition (SVD) method with the historic data of      . 
To implement the SVD procedure, first, we need to normalize the condition that sets 
   sums to 0 and    sums to 1. Since there are a series of combinations (  ,   ) to 
generate the same result of     , we choose one group as the standard benchmark with 
the normalization condition which distributes    equally around 0. With the 
normalization condition, then    must equal the average over time of           
                         
 
 
         
 
                         (1) 
Furthermore,    must (or almost) equal the sum over age of (           ), 
since the sum of    has been chosen to be unity. This is not an exact relation, however, 
since the error terms will not in general sum to 0 for a given age. Then, each    can be 
found by regressing, without a constant term, (           ) on    separately for each 
age group x. See Lee and Carter (1992) for details and further justification and statistical 
discussions. 
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Lee-Carter models mortality rate in two steps. First, the logs of the age-specific 
death rates are modeled as a linear function of an unobserved period-specific intensity 
index   , with parameters depending on    and   . The model accounts for almost all 
the variance over time in age-specific death rates as a group. Second, the index    is 
modeled as a time series of random walk with drift. Compared to the traditional hazard 
models, the Lee-Carter model accounts for the difference of mortality rate in age groups 
and describes the mortality time-series with a stochastic process. This is the benchmark 
for a series of extensions. 
2.2.2 Renshaw Haberman Model 
Renshaw and Haberman (2006) proposed a similar model to the Lee-Carter model 
but added a term to describe the cohort effect: 
                             
With the normalization condition: 
   
 
    
   
 
    
     
   
    
      
 
    
Here   ,   ,   ,      are defined as in to the Lee-Carter model. The variable      
captures the cohort effect and    is the parameter corresponding to it. The Lee-Carter 
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model is a special case where    and      are set to zero. The model captures the 
feature that individuals born in the same year have similar environments and healthcare, 
which affects the mortality rate and life expectancy. The cohort effect is described by 
    , for example, an individual aged 31 in year 2002 is in the same cohort with the 
individual aged 35 in year 2006, since they are born in the same year and t-x has the 
identical value of 1971. Figure 4 illustrates the cohort line. 
Figure 4 The Cohort Line 
  
There is also an identification problem in this parameterization. We need to 
introduce a normalization using a condition that the sum of      is equal to 0 and the 
sum of    is equal to 1 to reach the unique solution. In this way, the identification 
problem can be solved. 
2.2.3 Currie Model 
Currie (2006) introduced the simpler Age-Period-Cohort (APC) model which is a 
special case of the Renshaw-Haberman model with   =1 and   =1, namely 
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With the normalization condition: 
   
 
    
        
   
    
Currie (2006) applies P-splines to fit   ,    and       to ensure smoothness. 
2.2.4 Cairns-Blake-Dowd (CBD) Model 
Cairns, Blake and Dowd (2006) proposed the model for mortality rate: 
The forward survival probabilities              denotes the probability 
measured at   that an individual aged   at time 0 and still alive at    survives until 
time        
The model setup 
     
                     
                       
 
can be simplified in the format in accordance with the models above as: 
               
   
   
              
where      
       is the mean age in the sample range. This model has no 
identification problems. 
2.2.5 Cox-Lin-Wang (CLW) Model 
Cox, Lin and Wang (2006) proposed a model with permanent jump effects 
describing the evolution of the mortality factor    in the Lee Carter model as follows: 
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where μ and σ are constants, μ denotes the constant increment in the mortality factor   , 
σ denotes the volatility in the mortality factor   .      counts the number of the jumps, 
and      denotes the jump magnitude.    is a standard normal random variable that is 
independent of    and   . If a jump event occurs in year t+1, the magnitude of the 
jump,     , is included in the mortality factor     , and this jump effect persists forever. 
2.2.6 Chen-Cox Model 
Compared to the permanent jump in Cox, Lin and Wang (2006), Chen and Cox 
(2009) propose their model with transitory jump, that is described with the normal 
distribution. 
Let     describe the mortality factor when there is no jump event. They model 
    as a random walk with drift 
                   
where μ and σ are constants, μ denotes the constant increment in the mortality factor    , 
σ denotes the volatility in the mortality factor    . 
If a jump event occurs in year    , then,       . The jump      makes the 
actual mortality factor      change from       to      +    . Then 
                
If there is no jump in year    , then,        and 
           
Therefore, the dynamics of the mortality factor    can be completely expressed as 
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or 
                              
where μ and σ are constants, μ denotes the constant increment in the mortality factor   , 
σ denotes the volatility.      counts the number of the jumps, and    is a standard 
normal random variable that is independent of Y and N.  
Table 1 Model Comparison 
Model Description 
Lee-Carter 
Model 
The model is a function of age and time which is an improvement to the traditional 
hazard rate model which only depends on time. The projected value of the mortality 
rate captures the features that mortality rate increases with age and increases across 
the time. The model does not account for a cohort effect. 
 
Renshaw 
-Haberman 
Model 
The model is an extension/generalization of the Lee-Carter Model by adding a cohort 
effect term, which describes the year of birth. The model captures the feature that 
individuals born in the same year have similar environment, healthcare etc. 
experiences and so have similar affects on life expectancy.   
 
Currie 
Model 
The simpler Age-Period-Cohort (APC) model is a special case of the Renshaw-
Haberman Model. The P-spline method is applied to fit the data, which assumes that 
the mortality is a smooth surface.  
 
Cairns-Blake-
Dowd 
(CBD) Model 
The model is also a function of age and time, similar to the Lee-Carter Model. The 
difference is that this model applies the logit transform of mortality rates rather than 
the natural log of death rates as other models do. 
  
Cox-Lin-Wang 
(CLW) Model 
Extension of the Lee-Carter Model by adding a permanent jump effect term to the 
mortality factor kt. The severity of the jump follows a standard normal distribution 
 
Chen-Cox 
Model 
Similar to the CLW Model, this model entends the Lee-Carter Model by adding a 
transitory jump effect term to the mortality factor kt. The severity of the jump 
follows a standard normal distribution 
 
Brockett-Deng-
Macminn 
(BDM) Model 
This model extends the Lee-Carter Model by adding both longevity jump and 
mortality jump effect terms to the mortality factor kt. The arrival of the jump follows 
a Poisson process. The severity of the jump follows a double exponential 
distribution. 
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2.3 SUMMARY OF PRODUCTS FOR INDIVIDUAL LONGEVITY RISK TRANSFERRING 
Defined benefit plans are being changed to defined contribution plans in most 
countries' retirement markets. More and more individuals have to manage their own 
personal longevity risk. In the U.S., the baby boomers are entering their retirement age 
and need to address their own increasing longevity risk and the shortage of retirement 
plan payments. The retirees need to balance investment and consumption of their 
accumulated wealth. A key point that needs to be addressed is that extended lifespan may 
erode their accumulated wealth. Underestimation or overestimation of the personal life 
expectancy can negatively impact a retiree's life style. If the retiree overestimates his 
longevity, he will spend less than he could if he has purchased an annuity. If the retiree 
underestimates his longevity, he will spend aggressively and might outlive the 
accumulated wealth. 
In a survey (SOA, 2006), it was found that more than 40% of both pre-retirees 
and retirees underestimate average life expectancy by five or more years. Only 33% of 
retirees and 39% of pre-retirees have bought or plan to buy a product or choose a plan 
option that will provide them with guaranteed income for life. Similarly, a recent study 
(Scotti and Effenberger, 2007) in the UK retirement market suggests that individuals 
underestimate their own mortality by as much as five years on average. A defined benefit 
plan provides individuals with a guaranteed stream of payments, which decreases the 
chance of outliving the individuals' assets. The Scotti and Effenberger's study shows that 
individuals that retire without a pension plan have over an 80% chance of outliving their 
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assets, and individuals with a defined benefit pension plan have only an 18% chance of 
outliving their assets. 
Individuals without defined benefit pension plans choose to self-insure against 
longevity risk by making their own investment and consumption decisions or choose to 
do nothing because their income does not allow it. The investment decision is to select an 
asset allocation strategy among different investment instruments so as to diversify 
financial risk and minimize the chance of a portfolio shortfall. The consumption decision 
is to choose the level of withdrawal from the asset pool to reach a satisfactory life style. If 
individuals who try to self-insure are unsuccessful and run out of money, they will be 
forced to go through their remaining life without income. This would likely result in 
relying on children, relatives, or even federal programs to live out their remaining life, 
which is an undesirable situation for the self-insured individuals. So, a more reliable and 
scientific approach to manage the longevity risk for individuals is to transfer and 
diversify longevity risk with annuities and other financial instruments. 
Since a major trend in the retirement market is the declining number of defined 
benefit plans, there is an emerging opportunity for the expansion of the private market 
solution using financial instruments for individual longevity risk management. For 
individuals interested in insuring at least a portion of their longevity risk, there are 
several products that offer lifetime guarantees. These products include: 
 Immediate Annuities 
 (e.g., Single Premium Immediate Annuity, SPIA) 
 Impaired Life Annuities 
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 Deferred Annuities 
 Guaranteed Lifetime Withdrawal Benefits 
 Guaranteed Minimum Income Benefits 
 Advanced Life Delayed Annuities 
 Corporate Pensions 
 Reverse Mortgages 
 Structured Settlements 
 Life Settlements 
A brief description of each of the above is given below. 
2.3.1 Immediate Annuities 
An immediate annuity, or Single Premium Immediate Annuity (SPIA) is a 
classical type of annuity product that provides secured payment for life, usually paid for 
in a lump sum. The term of the contract varies in the frequency and amount of the income 
payment. They are structured to provide a fixed-level payment, a stream of payments that 
increase at a pre-specified rate, or a stream of payments that is tied to an underlying 
equity index (the latter being termed a variable immediate annuity, VIA). Some products 
provide that the period for the stream of payments continues until the death of the policy 
holder and some products provide for a certain period, irrespective of the death of the 
policy holder. Immediate annuities include several types of single-life policies, joint 
policies, and survivor policies. In the joint policies case, the annuity payments continue 
while two or more policy holders are alive. In the survivor policies case, the annuity 
payments continue while at least one of the policy holders is alive, although sometimes 
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with survivor policies the periodic income is reduced and only a percentage of the 
payment is received by the survivor after the first one dies. 
Some longevity risk products also embed options for hedging mortality risk, such 
as, the participating annuity (available in the U.K. market). Annuitants share in both the 
investment and longevity mortality gains while benefiting from risk pooling. Individuals 
can also benefit from other options in the form of minimum investment returns or from 
insurance benefits such as a minimum death benefit, minimum withdrawal benefit, 
minimum accumulation benefit, or a minimum income benefit. 
The quantification of longevity risk exposure is crucial to the pricing of 
immediate annuities. In the U.K., for example, regulators have recognized the effect of 
longevity risk and have adjusted the statutory reserving basis in accordance with this. The 
changes have been largely based on using revised projections for mortality improvements 
on a year-of-birth or cohort basis available from the Continuous Mortality Investigation 
Bureau, CMIB(2002). 
Longevity risk exposure can have a serious impact on the pricing of immediate 
annuities. Pricing risk is higher for companies who assume a larger mortality rate than the 
actual experience produces. Pricing risk is higher for the products issued to older 
individuals than to younger individuals. Because annuities for young people are for very 
long duration, they are more similar to perpetuity which pay forever (and which assumes 
the infinite lifetime and does not incorporate a mortality component). However, this 
observation does not mean that there is no exposure to longevity risk, only that the time 
value of money dominates for younger ages. There is still longevity risk. 
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Historical mortality rate data corresponding to individual types of products can be 
used to provide mortality table estimates that can be used in pricing the product. 
Regardless of the size of the population pool of the product, there can exist large 
variability in the estimate. This indicates that not only does the central estimate of the 
mortality rate need to be considered in the pricing, but also a measure of the uncertainty 
in the mortality rate should be accommodated to produce appropriate pricing margins. 
In the U.S., the immediate annuity market is mainly driven by individual sales. 
However, individual sales can be a problem due to adverse selection, since the product 
price is identical for individuals with different life expectancies. The individual who 
knows their life expectancy is lower than average will be more reluctant to purchase the 
product. As a result, the actual life expectancy in the pool will be higher than insurer 
expected. This can cause an underestimation of the product price and could produce a 
loss for the insurer. Adverse selection risk will be lower in the case of mandatory 
annuitizations, since the individuals with less life expectancy are also required to 
purchase the annuity. Such mandatory annuitization of accumulated funds occurs in the 
U.K. and reduces adverse selection effects exhibited by free purchase as in the U.S. 
Although the annuities are appropriate products for individuals to transfer 
longevity risk, the individual annuity market has not developed as fully as researchers 
expected. One reason is the lack of knowledge of the benefits of annuities and the general 
lack of knowledge of severity of the longevity risk problem. Another reason is the 
adverse selection problem which causes the high price of the product and deteriorates the 
attraction of the product. 
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2.3.2 Enhanced and Impaired Life Annuities 
Enhanced and impaired life annuities offer higher annuity payments to individuals 
who can prove that they are in poor health or are terminally ill. Enhanced and impaired 
life annuities can be created to provide longevity risk protection at a reasonable price for 
individuals who have a life expectancy lower than average. The products also help to 
solve the adverse selection risk in individual immediate annuities.  
Pricing and evaluation of the enhanced and impaired life annuities places a higher 
weight on exposure to a handful of impairments, particularly cardiovascular disease and 
conditions related to smoking. Due to the documented worse health condition of the 
annuitant, higher expected mortality rates are assumed for these policies. Therefore, the 
effect of longevity risk can be more serious, as there is likely to be less data on the 
mortality experience of particular subgroups of the population. The relative infrequency 
of incidence and poor historical reporting of cause of death will cause the estimate of 
mortality to be biased. The significant deviation in the medical underwriting process is 
another reason for biased life expectancy (Drinkwater, et al., 2006). 
2.3.3 Deferred Annuities 
Deferred annuities accumulate tax-deferred savings to distribute later as either an 
immediate annuity or as a lump sum payment. Fixed deferred annuities, variable deferred 
annuities, and equity indexed deferred annuities are the three categories. 
More recent products, such as Guaranteed Minimum Income Benefit (GMIB) 
policies, provide the option to annuitize and receive at least a minimum annuity payment 
at a price dependent on mortality and interest factors.  For GMIB policies, the long-term 
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interest rate and longevity risk are the two key risks. If the GMIB policy is based on 
incorrectly large assumptions for mortality, the cost to the issuer of the guarantee is 
increased. Moreover, since the interest rate in the capital market has been relatively low 
recently, the impact of the miscalculation of the interest rate is minor, compared to that of 
miscalculating the mortality rate (Richards and Jones, 2006). Another similar type of 
product is the Guaranteed Minimum Withdrawal Benefits policy. The risk level in this 
policy depends on the form of the guarantee. 
2.3.4 Advanced Life Delayed Annuities 
Advanced Life Delayed Annuities (ALDAs) are inflation-linked annuities sold to 
individuals in the early years of their lives that begin paying at age 80, 85, or 90. The 
cash flow and mortality insurance benefits cannot be exchanged before maturity. ALDAs 
act as the replacement for the defined benefit pension plan for individuals of advanced 
age. ALDAs do not include the accumulation phase to the same extent that traditional 
deferred annuities do. Therefore, they could be considered to be more tailored toward 
protection against catastrophic longevity (Milevsky, 2004). 
Pricing ALDAs depends on the annuitization rate and mortality table. Again, a 
biased estimation of the mortality rate could result in significant loss for the insurer. 
Moreover, a long-term risk is involved in the ALDA product. Since the product 
accumulates the premium for a long period before paying the benefits, the asset liability 
matching administration systems of most insurers do not support ALDA products very 
well. Assets to back the lengthy duration are not generally available, which exposes the 
insurer to reinvestment risk. There is no death benefit offered in the ALDA product, so 
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the policy holder could make years of premium payments and receive no benefit. This 
potential uncertainty leads to reluctance on the part of insurers to offer this type of 
product and policyholders to buy it (Milevsky, 2001). 
There is a subclass of the ALDA product called "longevity insurance." A lump 
sum premium is paid today for a benefit payment in the future. The deferral periods are 
usually in excess of 20 years. The advantage of the product is that it allows individuals to 
purchase insurance against outliving their assets at a much lower cost than traditional 
SPIA products (Milevsky, 2001). 
2.3.5 Corporate Pensions 
Corporate pensions include two categories: defined benefit (DB) and defined 
contribution (DC) plans. The retirement plans have certain tax advantages, and employers 
provide for a portion of the employee's contribution. Funds usually cannot be withdrawn 
without penalty before retirement. With a DB plan, the employer sets up a trust and 
contributes money annually in amounts sufficient to pay a defined retirement benefit to 
each employee. The employee receives a fixed income stream after retirement contingent 
on his/her salary, years of employment, retirement age and other factors. The fund is set 
up and controlled by the employer and the individual employee accounts are not 
segregated. With a DC plan, contributions are paid into individual accounts by each 
employee and the employer may contribute an additional amount. At retirement, a lump 
sum amount equal to the current account value is available. Defined contribution plans 
are versatile. The retiree has the options of creating a wide variety of ways to draw down 
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the fund value including simple ad hoc withdrawals or more well-defined withdrawals of 
a certain percentage of the value per year. 
Since DB plans guarantee a fixed stream of cash flows until the death of the 
policy holder, DB plans have a significant exposure to longevity risk and this risk is born 
by the employer who has set up the DB plan and administers it. Additionally, the pool of 
people in the same DB plans usually have similar features, including age, industry, 
occupation and location. These same risk characteristics can exaggerate the longevity risk 
presented by DB plans. Additionally, life expectancy is different for different 
socioeconomic groups (Richards, et al., 2006).  
Besides longevity risk, DB plans expose the employer to investment risk. When 
the investment return does not reach the expected level, the DB pension plans must raise 
contributions to fund the gap. For new employees they may adjust the formula for 
determining the pension payments. DB plans are also exposed to inflation risk. If wage 
inflation outpaces investment returns, pension plans that have benefits linked to final 
salary will have to increase contributions to the pension fund to account for anticipated 
salary growth over the employees' work life.  
DC plans expose the employer to less longevity risk since the plan provides the 
lump sum to the employees upon retirement, and is not linked to the lifetime of the 
employees. DC plans also expose the employer to less investment risk, since the 
participants make their own choice of the funds for investment. The participants, not the 
employer have to manage longevity risk and investment risk by themselves. The risk is 
still there, the difference is who must manage it. 
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Longevity risk exists in DB and DC plans. In DB plans, the employer is at risk. In 
DC plans, the employee is at risk. Increased life expectancy increases the needed net 
present value of pension provisions. Because people are living longer, employers or 
employees have to increase contributions to pension funds, or postpone retirement. The 
life table and mortality assumptions need to be adjusted for actuarial evaluation and the 
setup of pension schemes. Future pension plans administration must consider the 
substantial increases in life expectancy. 
2.3.6 Reverse Mortgages 
A reverse mortgage or life mortgage is a loan available to seniors, and is used to 
release the home equity in a property as one lump sum or multiple payments. The 
homeowner's obligation to repay the loan is deferred until the owner dies, the home is 
sold. The benefits of the product include: The homeowner does not need to sell the house. 
The homeowner can use the product to hedge their longevity risk if they choose to 
receive the loan as a series of annuity payments. The homeowner can make the illiquid 
housing asset more accessible. From the provider's perspective, longevity risk, real estate 
price risk and interest rate are the major risks involved in the reverse mortgages. In the 
U.S. market, Home Equity Conversion Mortgage (HECM) program, Fannie Mae's Home 
Keeper program, and Financial Freedom's Cash Account Advantage are three major 
reverse mortgage programs. Collections (pools) of reverse mortgages can be bundled and 
securitized to produce assets. The structure of securitization for reverse mortgages is 
similar to that for a collateralized debt obligation (CDO). The valuation of the reverse 
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mortgage, its cash flows and timing, and its structured derivatives securitized asset all 
depend on using a quantitative model of the mortality rate and life expectancy. 
2.3.7 Life Settlements 
A life settlement is a financial transaction in which the owner of a life insurance 
policy sells an unneeded policy to a third party for more than its cash value and less than 
its face value. A life settlement is an alternative a policyholder has to either surrender or 
lapse this policy when the owner of the life insurance policy no longer needs or wants the 
policy. This is also an alternative when the policy is underperforming or the policy owner 
can no longer afford to pay the premiums. Investment banks have purchased hundreds of 
thousands of these life insurance policies and repackaged (securitized) them into bonds, 
then sold bonds to investors such as pension funds. The payment of the bond depends on 
the life expectancy of the members in the pool of the life insurance policies. "We 
estimate that life settlements, alone, generate surplus benefits in excess of $240 million 
annually for life insurance policyholders who have exercised their option to sell their 
policies at a competitive rate." (Doherty and Singer, 2002). Most purchasers of this type 
of contract are not in the primary business of trying to make profits from mortality. The 
cash flows from the life settlements clearly involve longevity risk while the insured lives. 
2.4 SUMMARY OF PRODUCTS FOR INSTITUTIONAL MORTALITY AND LONGEVITY RISK 
TRANSFERRING 
2.4.1 Mortality Bonds 
The Swiss Reinsurance company issued the first mortality risk contingent 
securitization in December 2003, the Swiss Re Mortality Catastrophe Bond. When the 
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bond covenants are triggered by a catastrophic evolution of death rates of a certain 
population, the investors incur a loss in principal and interest. The bond provides the 
investor higher yield than that in the usual bond market as a compensation for the 
additional mortality risk the bond purchaser takes. The bond was issued through a special 
purpose vehicle (SPV) called Vita Capital. This securitization enables the Swiss Re to 
take extreme catastrophe mortality risk off its balance sheet, such as the Japan tsunami 
disaster that killed thousands of policy holders. Then Swiss Reinsurance has capital freed 
up on that bond just when they needed it for claims. Similar products will be of interest to 
companies that self insure workers compensation. 
The bond had a maturity of three years, a principal of $400m, and a coupon rate 
of 135 basis points plus the LIBOR. The mortality index,   , that was the weighted 
average of mortality rates over five countries, males and females, and a range of ages. 
The principal would be repayable in full only if the mortality index does not exceed 1.3 
times the 2002 base level during any year of the bond's life, and is otherwise dependent 
on the realized values of the mortality index. The precise payment schedules are given by 
the following    functions: 
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Thus, if the mortality rate does not exceed 130% of the normal mortality defined 
at time 0 as   , then all coupons and principal are given. If mortality    does exceed 
130% of   , then principal repayment is lost; all is lost if the mortality is 150% above 
the declined level   . 
2.4.2 Longevity Bonds 
The European Investment Bank (EIB) announced a possible issue of the EIB/BNP 
Paribas Longevity Bond in November 2004, though the structurer/manager BNP Paribas. 
The bond was issued through a Bermuda-based reinsurer Partner Re. Partner Re 
contracted to make annual floating rate payments (equal to £50m ×    to the EIB based 
on the realized mortality experience of the population of English and Welsh males aged 
65 in 2003 (published by the U.K. Office for National Statistics). Partner Re would 
receive from the EIB annual fixed payments based on a set of mortality forecasts for this 
cohort. The mortality forecasts used for the first payments were based on the U.K. 
Government Actuary's Department 2002-based central projections of mortality, adjusted 
for Partner Re's own internal revisions to these forecasts. This arrangement was then 
supplemented by a cross currency swap (i.e., fixed-sterling-for-floating-euro) interest-rate 
swap between the EIB and BNP Paribas, since the EIB also wished to pay a floating rate 
in Euros. The bond had an initial value of £40 m, an initial coupon of £50 m, and a 
maturity of 25 years. The floating payment structure is         £50m ×    for 
                For lack of investor interest, the longevity bonds were not issued 
successfully. 
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2.4.3 Longevity Swaps 
There are two types of longevity swaps. Of interest here is a cash-flow swap that 
indemnifies one party and this type of swap is an over-the-counter transaction. An 
example of this is the q-forwards proposed by JP-Morgan. These were intended to be 
simple capital market instruments for transferring longevity risk and mortality risk. The 
q-forwards enable pension funds to hedge against increasing life expectancy of plan 
members and also enable life insurers to protect themselves against significant increases 
in the longevity of policyholders. Similar to other forward swaps, q-forwards are 
securities involving the exchange of a fixed rate payment for a floating or variable rate 
payment. In this case, the q-forward variable payment depends on the realized mortality 
of a population at some future date, whereas the fixed rate is dependent on a fixed 
mortality rate agreed at inception. The q-forwards form the basic building blocks from 
which many other complex securities can be constructed. The q-forwards provide a type 
of standardized contract which can help to create a liquid market. A set of q-forwards that 
settle based on the LifeMetrics Index could fulfill this role. Since the investors require a 
risk premium to take on longevity risk, the mortality forward rates at which q-forwards 
transact will be below the expected, or "best estimate" mortality rates. The other swap 
type is basis risk and may be over-the-counter or exchange based.  
A q-forward contract to hedge the mortality risk of a life insurer is that a life 
insurer pays fixed mortality rate to JP Morgan and JP Morgan pays realized mortality rate 
to the life insurer. A q-forward contract to hedge the mortality risk of a pension fund is 
that a pension fund pays realized mortality rate to JP Morgan and JP Morgan pays the 
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fixed rate to the pension fund. In this way, the pension fund who longs the longevity risk 
transfers the risk to the life insurer who shorts the longevity risk. 
Table 2 Comparison of Products 
Date Mortality Bonds Longevity Bonds Longevity Swap 
Example Swiss Re Mortality 
Catastrophe Bond 
 
EIB/BNP Paribas LB q-Forwards 
Purpose Hedge Mortality 
Risk for Issuers 
Hedge Longevity 
Risk for Holders 
Hedge Mortality Risk for Fixed 
Rate Payers 
Hedge Longevity Risk for Fixed 
Rate Receiver 
 
Participants Issuer:  
Life Insurance  
Reinsurance 
Holder: 
Pension 
Annuity Providers 
Fixed Rate Payers: 
Life Insurance or Reinsurance 
Fixed Rate Receivers: 
Pensions Annuity Providers 
 
Maturity Short Term 
 
Long Term Flexible Term 
Coupon High Yield 
 
Low Yield N/A 
Structure 
 
Complex Complex Simple 
Underwriting Fees High High Low 
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Table 3 Publicly Announced Longevity-Swap Transactions 
Date Hedger Size  
(m Pounds) 
Format Term Comments 
Jan 
2008 
Lucida 
(Insurer) 
Not disclosed Derivative 10 years Index-based longevity swap 
First capital markets longevity hedge 
 
July 
2008 
Canada Life 
(Insurer) 
500 Derivative 40 years Indemnity longevity swap 
Distributed to capital markets        
investors 
 
Feb 
2009 
Abbey Life 
(Insurer) 
1,500 Insurance Run-off Indemnity longevity swap 
Distributed to reinsurers 
 
Mar 
2009 
Aviva 
(Insurer) 
475 Derivative 10 years Collared indemnity swap 
Distributed to reinsurer and capital 
markets 
 
Jun  
2009 
Babcock  
International 
(Pension fund) 
1,200 Derivative 50 years Indemnity longevity swap 
First longevity hedge by a pension 
scheme 
 
July 
2009 
RSA 
(Pension fund) 
1,900 Insurance Run-off Indemnity longevity swap 
Distributed to reinsurers 
 
Dec 
2009 
Royal County of 
Berkshire 
(Pension fund) 
750 Insurance Run-off Indemnity longevity swap 
First longevity hedge by public 
sector 
 
Feb 
2010 
BMW UK 
(Pension fund) 
3,000 Insurance Run-off Indemnity longevity swap 
Distributed to reinsurers 
 
Jul 
2010 
British Airways 
(Pension fund) 
1,300 Insurance Run-off Indemnity longevity swap 
Distributed to reinsurers 
Source: McWilliam, Longevity Risk, 2011 
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Table 4 Comparison of customized and indexed longevity products 
 Customized 
(indemnity)hedge 
Index (parametric) hedge 
Longevity risk 
indemnification 
Perfect hedge 
No basis risk 
Customized for the 
portfolio of hedged lives 
 
Not perfect hedge 
With basis risk 
Expected to hedge around 85% of 
risk 
What is hedged Hedge of pension plan cash 
flow 
Hedge of liability value over life 
of swap 
 
Target For pensioner members  
 
For deferred members 
Data 
requirements 
Requires pension plan to 
provide data over the life of 
hedge 
Pension plan member data only 
required initially to structure 
hedge as payout of hedge is based 
on published index 
 
Other Bespoke contract tailored to 
structure of pension plan 
Standardized contract 
More attractive to capital markets 
investor base 
Promotes secondary liquidity 
Source: Revised from McWilliam, Longevity Risk, 2011 
 
The following section introduces the mortality models currently used for 
modeling mortality and longevity risk and how the anticipated mortality improvements 
are incorporated. The next section discusses the q-forward derivative instrument of J.P. 
Morgan and shows how to price the product in closed form by using a new double 
exponential jump diffusion model extension of the Lee-Carter mortality formula that 
allows for cohort and age effects. A final section discusses future research and further 
application to life settlement securities, reverse mortgages, and longevity sensitive 
products. 
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Chapter 3 Double Exponential Jump Diffusion Model 
Pricing of the CAT mortality bonds or life-settlement securities depends on the 
estimation and forecast of mortality rates or life expectancy, which are considerations 
involving mortality risk and longevity risk. The estimation and forecast of life expectancy 
or mortality rate also plays a crucial role in longevity/mortality risk management for 
pension funds or insurers. In this paper, we propose a stochastic model, based on the 
Brownian Motion process, plus an asymmetric jump diffusion process for the estimation 
and forecasting of mortality rates and life expectancy. 
Longevity jumps and mortality jumps should be incorporated in the modeling and 
securitization (Cox, Lin and Pedersen 2010), since the jumps are the critical sources of 
risk which pension funds and insurers should be more cognizant of (Zanjani, 2002). The 
mortality jumps (such as the 1918 flu) have a short-term intensified effect, while the 
longevity jumps (caused by the pharmaceutical or medical innovation) have long-term 
gentle effect. The different frequency and intensity of the mortality jumps and the 
longevity jumps explain the distribution skewness of the mortality time-series increment, 
which is important but not considered in previous mortality rate models. Considering the 
asymmetric jump phenomenon of the mortality time-series, our model adopts a 
compound Poisson-Double Exponential Jump Diffusion (DEJD) process to capture the 
longevity jumps and the mortality jumps, respectively. 
Very few studies address the modeling of mortality jumps for securitization. 
Biffis (2005), Bauer, Borger and Russ (2010) apply affine jump-diffusion process to 
model force of mortality in a continuous-time framework. Our model incorporates the 
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cohort effect, which captures the mortality time-series and adjusts it to fit different age 
groups. The model with cohort effect captures the feature of the historical mortality time-
series more accurately. Chen and Cox (2009) model the jump process with a compound 
Poisson normal jump diffusion process. Our model makes the contribution of applying 
the double exponential jump diffusion which differentiates the longevity jumps and the 
mortality jumps. This captures the distribution skewness of the mortality time-series 
increment and offers better fitness. Cox, Lin, and Pedersen (2010) propose a model to 
accommodate both longevity jumps and mortality jumps. Our model has fewer 
parameters, more concise specification, and can be easily parameterized and applied to 
securitization. 
Our model incorporates the advantages of the Lee-Carter mortality framework, 
which describes the mortality time-series and considers the cohort effect, making age-
specific adjustment for different age groups. This adjustment is critical for the model, 
since the mortality improvement and extreme positive or negative events (such as 
influenza pandemic) have different intensity levels in different age groups. In this way, 
the Lee-Carter model appropriately describes the three dimensional surface of the 
mortality rate with respect to time horizon and age group horizon. The Lee-Carter 
framework has been extended by Brouhns, Denuit and Vermunt (2002), Renshaw and 
Haberman (2003), Denuit, Devolder and Goderniaux (2007), Li and Chan (2007), Chen 
and Cox (2009), Lin and Cox (2005), Lin and Cox (2008). 
We test our model with historical data and make model fitness comparisons with 
previous models. The results clearly illustrate the advantage of our model in terms of fit. 
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In our application, we use the first CAT mortality bond, the Swiss Re Catastrophe 
Mortality Bond (2003) to calculate the implied risk premium, with two types of changing 
measure approaches. We implement our model to price the q-forward longevity risk 
derivative as an example, which illustrates the benefit of our model for providing a 
closed-form pricing solution for standard structure mortality linked securities. The q-
forward derivative, proposed by JP Morgan based on the LifeMetrics index, has the 
potential to be a future standardized contract which can help to create a liquid market. 
Beyond the q-forward, our model can provide closed-form pricing solutions to all the 
mortality-linked securities with cash flows that are linear functions of the mortality rate 
for each period. 
3.1 DATA DESCRIPTION 
The historical data come from HIST290 National Center for Health Statistics. We 
chose this because it is the same data used in Chen and Cox (2009). This allows us to 
compare results and model fit (which we do in section 4). We use the same data in order 
to facilitate the model fitness comparison in Section 4. The data lists death rates per 
100,000 populations for selected causes of death. Death rates are tabulated for age group 
(<1), (1-4), (5-14), (15-24), then every 10 years thereafter, to (75-84), and finally, the last 
group is (>85). The data includes both sexes and several race categories. Selected causes 
for death include major conditions such as heart disease, cancer, and stroke. Figure 5 
shows the mortality rate for different age groups and years. Figure 6 shows the 
comparison of the mortality rate for several sample age groups, including relatively older 
groups and younger groups. 
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Figure 5 1900-2004 Mortality Rates 
 
We can observe clearly two mortality rate trend properties from Figure 5 and 
Figure 6. In Figure 5, the downward trend indicates that the mortality rate follows a 
decreasing trend during 1900-2004, at all ages. For example, in the over 85 age group, 
the mortality rate decreases from 0.26 to 0.14, while in the younger age groups, such as 
15-24, the mortality rate decreases from 0.006 to 0.0008. The decreasing trend shows the 
improvement of the life times or longevity in all age groups. 
In Figure 6, the change in the mortality rate in the older-age groups is more 
significant than that in the younger-age groups with a steeper downward trend. For 
example, the mortality rate decreases 0.12 in the age group over 85. During the same time 
period, the mortality rate decreases only 0.0052 in the age group 15-24. The comparison 
of the steepness of the mortality surface shows that the improvement in longevity among 
the older-age group is more significant than that in the younger-age group. We can 
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observe that there is variability and dynamics in the mortality trends. Accordingly we 
shall use a stochastic model to capture the dynamics features. 
Figure 6 Comparison of the Age Group Mortality Rates   
    
3.2 MODEL FRAMEWORK AND REQUIREMENT 
The basic requirement of the mortality model is to capture the features described 
by the data. Various mortality rate models have been provided by previous research. The 
majority of models are based on the Lee-Carter one-factor model (Lee and Carter, 1992). 
These models extend the Lee-Carter model to a two-factor model (Blake, Cairns, and 
Dowd, 2006a), or incorporate a stochastic process in the model (Dahl 2004), or introduce 
the possibility of a jump process in the stochastic process to accommodate extreme 
outliers in the mortality time series (Cox, Lin, and Wang 2006; Chen and Cox 2008).  
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In the Lee-Carter framework, the mortality rate      denotes the mortality rate of the 
group whose age is x during the year t. It is decomposed into age-specific parameters   , 
   and mortality time-series   . 
                                                                                           (3) 
                                                                                       (4) 
 Here    represents the age group shift effect, and        ) is the general shape 
across the age of the mortality schedule, and    represents the age group's reaction 
effect to the mortality time-series   . In other words, the    profile tells us which group 
of mortality rates decline rapidly and which group of mortality rates decline slowly in 
response to temporal changes in mortality   , and      captures the age group's residual 
effect not reflected in the model. Lee and Carter (1992) suggest estimating the parameters 
in their model using a two-stage singular value decomposition (SVD) based on historical 
data for      to estimate the age-specific parameters   ,   , and to generate the 
mortality time-series   . 
To implement the SVD procedure, first, we need to normalize using a condition 
that the sum of    is equal to 0 and the sum of    is equal to 1. This enables the sum of 
   to be unity and distribute the    equally around 0. Then    must equal the average 
over time of          . 
                                                
 
 
         
 
                           (5) 
Furthermore, by equation (2),    must (or almost) equal the sum over age of 
(         -  ), since the sum of    has been chosen to be unity. This is not an exact 
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relation, however, since the error terms will not in general sum to 0 for a given age. Then, 
each    can be found by regressing, without a constant term, (         -  ) on    
separately for each age group x. 
In the second stage, we re-estimate the mortality time-series    iteratively, given 
the estimation of    and    in the first step. This enables the actual sum of death at 
time t (left-hand side) to equal the implied sum of deaths at time t (right-hand side). 
                                                                                  (6) 
where    is the actual sum of deaths at time t , and      is the number of members of 
population in age group x at time t. 
Implementing the SVD two-stage procedure with data on historical U.S. mortality 
rates during 1900-2004, we obtain the fitted   ,   , in Table 5, and the mortality time-
series    in Figure 7. The decreasing trend of mortality time-series    shows the 
improvement of mortality along the time as described previously. Figure 7 also shows the 
big jump in 1918 (which was caused by the flu pandemic) and other jumps around 1920, 
1943, etc. 
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Table 5 Fitted Value for Age-Specific Parameters     and    during 1900-2004 
Age Group       
<1 -3.4087 0.1455 
1-4 -6.2254 0.1960 
5-14 -7.1976 0.1492 
15-24 -6.2957 0.0994 
25-34 -5.9923 0.1044 
35-44 -5.4819 0.0855 
45-54 -4.7799 0.0608 
55-64 -4.0137 0.0468 
65-74 -3.2347 0.0426 
75-84 -2.4196 0.0409 
>85 -1.6119 0.0290 
Figure 7 The Mortality Time-Series    
    
Now, we need a model to capture the features of the shape, the trend and the jumps 
of the mortality time-series   . First, the model should incorporate a stochastic term in 
the description of the    time series, as this has proved to be better than using the model 
without the stochastic process, (Dahl 2004). Second, as shown in Figure 7,    includes 
both positive and negative values. Since geometric Brownian motion will not generate a 
negative value from the positive starting value, it does not fit the    process by itself. 
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However, Brownian motion can be selected to fit the    time series. Third, we can 
observe from Figure 7 that the jumps are transient, not permanent. For example, the 
sudden increase of mortality rate in 1918, caused by the flu, falls back to the normal 
condition after two years. 
Beyond the three points on the model specification listed above, we noted that, 
the jump phenomenon in mortality rates is two directional. In Figure 7, the positive jumps 
(the sudden increases in the mortality time-series) occur with higher-severity, while the 
negative jumps (the suddenly decreases in the mortality time-series) are of lower-severity 
and higher-frequency. Coughlan et al., 2007 also shows that there is a significant negative 
autocorrelation in mortality rates, so increase in mortality are often followed by increases 
in longevity. However, there is a definite downward trend in mortality with the jumps 
being asymmetric and of unequal frequency. Hence, the model that involves a jump 
process with a symmetric normal distribution for the size of the jump (Chen and Cox, 
2009) may not adequately capture the asymmetry of the mortality jump phenomenon. 
From biological and demographic perspectives, the positive jumps (mortality jumps) can 
be explained by sudden catastrophes (e.g., earthquake, tsunami, hurricane) or critical 
diseases, such as the extreme positive jump caused by flu in 1918. These positive jumps 
can be transitory (1918 flu) or more lasting (AIDS, antibiotic resistant strains of 
tuberculosis, etc.). The negative jumps (longevity jumps) are associated with multiple 
biological and health improvement causes. According to Johnson, Bengtson and Coleman 
(2005) increases in survival currently reflect a shift in the causes of death from infections 
to chronic degenerative diseases. Hence, the improvements in mortality due to health or 
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biological reasons affecting chronic diseases appear more frequently and are of a more 
moderate size over time. The health improvements due to improved medical treatment, 
for example, may be frequent in occurrence and small in impact, but they have gradually 
but significantly changed life expectancy. Illustrative of this, since 1960 longevity has 
increased 1-1.5 % per year due mainly to a 65% reduction in cardiovascular events in the 
age cohort over age 45 (Iacovino 2009). Again the survival jump effect could be lasting 
or transitory (e.g., a new drug which loses effectiveness). A large longevity jump could 
occur in the future if an effective treatment of coronary heart disease or cancer were 
found, as these two causes of death combined constitute more than half of all deaths 
among people over the age of 40 (Johnson, Bengtson and Coleman 2005 p. 109). 
Ultimately, once the jump (positive or negative) occurs, any lasting effect can be 
subsequently captured in the Gaussian process component of the model. Because the 
negative jumps are low severity and high frequency they are difficult to discern in the 
figure except possibly in a more negatively inclined series. 
The descriptive statistics of             show leptokurtic features. The 
skewness of      equals to -0.451. In other words, the      distribution is skewed to the 
left, and has a higher peak and two heavier tails than those of a normal distribution, 
which we can also observe in Figure 8. 
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Figure 8 Comparison of Actual      Distribution and Normal Distribution 
    
In Figure 8, the histogram represents the distribution of actual     , and, as can be 
seen,     cannot be fitted well by a normal distribution. Hence, the Brownian motion 
process alone cannot be used to describe the mortality time-series   . 
To incorporate the leptokurtic feature of the      distribution, the analysis here 
incorporates a double exponential jump diffusion (DEJD) model to capture both the 
positive jumps and negative jumps of the    process. Compared to Cox, Lin, Pedersen 
(2010), which also captures the positive jumps and negative jumps (the size of the jumps 
is normally distributed so there is symmetry in the distribution in Cox and Chen), our 
model has a concise specification and an easy approach for calibration. What is more, 
unlike Cox et al. (2008), our model has a closed-form solution for the forecast of the 
future mortality rate, which facilitates mortality securities pricing. 
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3.3 THE MODEL SPECIFICATION 
To capture the features of the mortality time-series   , and to account for the 
tractability and the calibration of the model, we set the model specification to 
describe      in the approximate continuous-time model of      as given below. 
The dynamics of the mortality time-series    is specified as 
                                                 
    
                        (7) 
where    is a standard Brownian motion,      is a Poisson process with rate λ, where 
λ describes the expected frequency of the jumps. The larger the λ, the more times jumps 
occur in the mortality time-series. Here    is a sequence of independent identically 
distributed (iid) nonnegative random variables,           has an double exponential 
distribution with the density 
                                     
               
                           (8) 
                              
The parameters   and   represent, respectively, the proportion of positive 
jumps and negative jumps among all jumps. Thus, pλ is the expected frequency of 
positive jumps and qλ is the expected frequency of negative jumps. The parameters    
and    describe the positive jump severity and the negative jump severity separately. 
Thus, Y|Y≥ 0 is exponentially distributed with mean   
  , while -Y|Y≤ 0 is 
exponentially distributed with mean   
  . The larger   , the smaller the positive jumps 
severity. Similarly, the larger    the smaller the negative jump in absolute value. In this 
way, the positive jumps and negative jumps are captured by similar distributions but with 
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different parameters, based on the asymmetry of jumps in the mortality time-series    
and the leptokurtic feature of    . 
The model specification with the double-exponential distribution has the 
advantage of mathematical tractability allowing a closed-form formula for the expected 
future mortality rate to be derived. Because of this closed-form solution, the DEJD model 
may provide a useful stochastic mortality model for internal company mortality 
simulation, as well as being useful in the capital market applications we discuss 
subsequently. The double-exponential distribution has also been widely implemented as a 
stock price jump-diffusion model, for which closed-form solutions for options and other 
securities are available (Kou, 2004). The closed-form solution of the expected future 
mortality rate is presented in equation (20). 
3.4 NUMERICAL SOLUTION 
3.4.1 Parameter Calibration 
The disentangling of jumps from the diffusion components is a serious difficulty 
in the calibration of the underlying processes. The increments of the underlying process 
are supposed to be captured by the diffusion process, with a few extreme increments 
captured by jumps. However, the addition of the jump process may yield the wrong 
calibrated parameters which leads to high frequency of jumps and small severity of 
jumps. The double-exponential jump diffusion model for     faces the same problem. A 
calibration method is needed to generate the right parameters of low frequency and large 
severity for jumps. Ait-Sahalia and Hansen (2004) demonstrate that maximum likelihood 
estimation (MLE) has advantages in disentangling jumps from diffusion. Meanwhile, the 
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double-exponential jump diffusion is a linear process with independent increments and an 
explicit transition density, which fortunately satisfies the requirement of a complete 
specification of the transition density for using MLE. Therefore, we choose the MLE 
method to calibrate parameters                 with the     time series. 
Let                denote the mortality time-series, at equally spaced times 
           By (6), the one period increments                is independent 
and identically distributed (iid). The unconditional density of one period increment f(r) is: 
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where         
      
  
          
      
  
  and        is the conditional density for 
a one period increment, conditional on the given number of up and down jumps       
in the increment.  
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                                           (13) 
The log-likelihood given T equally spaced increment observations is 
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where        , and   
  
 
. Then we can calibrate the parameters 
               . 
After computation, we get                   ={0.029,0.035,0.71,0.75;-
0.20,0.31}, and                ={0.064,0.45;0.71,0.75;-0.20,0.31} and maximum 
likelihood value         . Here    and    describe the severity of positive jumps 
(mortality jumps) and negative jumps (longevity jumps), respectively. A larger   
represents a smaller severity. The fact that   = 0.71< 0.75=    verifies that the severity 
of positive jumps is larger than the severity of negative jumps, consistent with that 
observed in Figure 7. Here    and    describes the frequency of positive jumps and 
negative jumps, respectively. A larger λ represents a larger frequency. Since   = 
0.029<0.035=   , this verifies that the frequency of positive jumps is smaller than the 
frequency of negative jumps, consistent with that observed in Figure 7. 
3.4.2 Model Comparison 
Figure 9 shows how the DEJD model fits the actual increment of mortality 
rate     , by comparing the distribution generated by the DEJD model calibrated to 
historical data and the actual distribution of     . Comparing Figure 9 with Figure 8, we 
observe that the DEJD extension of the Lee-Carter model approximates the distribution 
of increment of mortality rate      much better than the commonly used Brownian 
motion extension. The mean of the distribution of DEJD and the Brownian motion is the 
same,                , however the standard deviation of the distribution of 
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DEJD (                   ) is much less than that for the Brownian Motion 
model. This is exactly the reason that the DEJD model is more appropriate to fit the 
actual distribution, which can be directly observed from the comparison of the two 
figures. The underlying reason is that the Lee-Carter model includes the outliers in the 
Brownian motion diffusion process, which causes the calibrated     to be larger. And 
the Brownian motion diffusion is appropriate to capture the normal distribution shape 
without a fat tail and a high peak, however this is not the case in this data. In our DEJD 
model, we include the outliers in the jump diffusion part, which enables the calibrated 
      to be smaller than     and improves the fit to the data. 
Figure 9 Comparison of Actual     Distribution and DEJD Distribution 
 
Next, the DEJD model is compared with both Lee-Carter Brownian motion model 
and the normal jump diffusion model (Chen and Cox, 2009). For model selection, we 
adopt the Bayesian Information Criterion (BIC) proposed by Schwarz (1978). Unlike the 
 51 
significance test, BIC allows comparison of more than two models at the same time and 
does not require the alternatives to be nested. BIC is a "conservative" criterion since it 
heavily penalizes over parameterization (Ramezani and Zeng, 2007). 
Suppose the kth model   , has parameter vector   , where    consists of    
independent parameters to be estimated. Denote     as the MLE of   . Then, BIC for 
Model    is defined as: 
                                               
 
                               (14) 
where m is the number of observations in data set C and             is the maximized 
likelihood function. With the BIC criterion, the best "fitting" model is the one with the 
smallest BIC value. Table 6 below gives the BIC model fit values for the three competing 
models. It uses the maximum likelihood function values provided in (Chen and Cox, 
2008). It can be observed that the DEJD model fits best2 
 
 
                                                 
2 The DEJD model fits the real series of 104 data points better than the other models in spite of being 
penalized by the BIC criterion for having more parameters. We do get the same ranking of the models by 
log likelihood fit as by BIC, even if we exclude the 1918 flu year from the data (which we do not think 
should be done). However, if the 1918 flu year is excluded and the series is made artificially smoother, then 
using the BIC criterion, the parameter penalty dominates and the ranking is simply according to the number 
of parameters in the model (Lee-Carter with two parameters, then Chen Cox with 5 parameters, then DEJD 
model with 6 parameters). 
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Table 6 Comparison of Model Fitness 
 Number of  
Parameters 
ln (likelihood) BIC 
Double Exponential Jump Diffusion Model (DEJD Model) 
 
6 -49.95 127.76 
Normal Jump Diffusion Model (Chen-Cox Model) 
 
5 -62.52 148.26 
No Jump Diffusion Model (Lee-Carter Model) 2 -94.27 197.82 
 
The underlying reasons that our DEJD model fits the data better are as follows. 
First, the outliers in the mortality time-series cause there to be fat tails and a high peak in 
the increment      distribution which rules out the normal distribution. The Lee-Carter 
model treats outliers the same as other points in the mortality time-series evolution 
process. As a result, the outliers enhance the variability of the process and cause 
overestimation of the standard deviation σ. Our DEJD model applies a compound Poisson 
double exponential jump diffusion process separately from the Brownian motion 
diffusion process. This avoids the problem of mismatching the fat tail and high peak with 
the normal distribution and hence provides a better fit. 
Second, the Chen-Cox model applies the normal jump diffusion model which is 
composed of a Brownian motion diffusion process and a normal jump diffusion process. 
This model also treats the outlier with a normal distribution. Actually, the positive outlier 
(or jump) and the negative outlier (or jump) are due to different biological and technical 
reasons. The positive outliers (for example, that caused by the 1918 flu pandemic) have 
short-term intensified effects, while the negative outliers (caused by pharmaceutical or 
medical innovation) have long-term gentle effects. The different frequency and intensity 
of the positive outliers and the negative outliers explain the skewness of the mortality 
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time-series increment, which is not appropriately described by the symmetric normal 
jump diffusion. 
The BIC comparison above shows the model with asymmetric jumps fits the 
mortality time-series     better than the Lee-Carter model or the Chen-Cox model. An 
important feature of the data is the 1918 flu epidemic. In our view, the flu is in the data, 
might recur, and should therefore be included in any model, especially one aimed toward 
financially hedging against such events in the future. In an alternative view, Lee Carter 
treated it as an outlier, essentially regarding it as a one of a kind event whose inclusion 
would result in misleading average forecasts. Additionally, Chen Cox (2010) and Li and 
Chan (2005, 2007), in order to reveal a smoother mortality trend, performed a systematic 
time-series outlier analysis for the mortality data in United States and Canada, and fit the 
adjusted outlier-free mortality series to the Lee--Carter model. In their data, U.S., 1900 to 
2000, they find seven outliers, which occurred in years 1916, 1918, 1921, 1928, 1936, 
1954, and 1975, respectively. Most of these outliers result from influenza epidemics 
according to their explanations, except for the data in 1954 and 1975. To explore the 
effect of such deletions on our model, we did another analysis where we deleted the 
outliers found by Li and Chan from the original mortality data, and re-estimated the 
mortality factor    . The parameters obtained were {0.01,0.05,0.92,0.85,-0.23,0.39}, and 
the ln(likelihood) value was {-47.62} with a BIC value of 123.1063. The maximum 
likelihood value is similar as the result treated by Chen Cox model and Lee Carter model. 
(Chen Cox 2010). When the jumps are treated as outliers and deleted from the trend, the 
parameters describing the arrival of the positive jump or negative jump converge to 0. 
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The parameters describing the Gaussian component (drift and volatility) converge to that 
in the Lee Carter model. 
However, almost surely catastrophic mortality event will occur again, the question 
is only when, and how can vulnerable entities (life insurers, pension funds, etc.) prepare 
for it and mitigate their financial exposure to this risk. For the purpose of this paper, the 
rationale for the interest in mortality and longevity risk is precisely to be able to handle 
such outliers as the 1918 flu pandemic. If, on the other hand, the purpose were to model 
mortality rates alone for aggregate smooth life table models, such as the goal of Lee- 
Carter, then their removal prior to parameter fitting might be justified. In our case if there 
were no possibility of jumps, especially large potentially bankrupting jumps in mortality 
or longevity rate, then there would be no interest in longevity or mortality derivatives to 
be introduced into the capital markets. It is precisely because of such jumps that the 
problem arises and hence we strongly feel that the inclusion of these outliers should be 
maintained. Having said that, without the 1918 outlier, as expected, the BIC improves 
since one is fitting a smoother series. Still, we feel that the outlier point needs to be 
included as a matter of principle. 
3.4.3 Implied Market Price of Risk 
Like other insurance products, such as annuities, the longevity risk contingent 
securities are priced in an incomplete capital market. Hence, the risk premium should be 
considered in pricing the issues, since it represents the price that pension funds or 
insurers are willing to pay to transfer longevity or mortality risk. In previous research 
papers, (Blake, Cairns, Dowd, MacMinn 2006), (Chen, Cox 2009), the Swiss Re 
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mortality catastrophe bond has been used to calculate the implied mortality risk premium, 
given its payment structure and issue price. 
    The Swiss Re Mortality Catastrophe Bond 
The Swiss Reinsurance company issued the first mortality risk contingent 
securitization in December 2003. If the bond is triggered by a catastrophic evolution of 
death rates of a certain population, the investors incur a loss in principal and interest. The 
bond provides the investors higher yield as compensation for the mortality risk they take. 
The bond was issued through a special purpose vehicle (SPV) called Vita Capital, which 
enabled Swiss Re to remove extreme catastrophic risk from its balance sheet. 
The bond had a maturity of three years, a principal of $400m, the coupon rate of 
135 basis points plus LIBOR rate. The mortality index,   , was a weighted average of 
mortality rates over five countries, males and females, and a range of ages. The principal 
was repayable in full only if the mortality index did not exceed 1.3 times the 2002 base 
level during any year of the bond's life. If mortality did exceed this threshold, the 
payment was dependent on the realized values of the mortality index. The precise 
payment schedules were given by the following   functions:     
    
                                                          
                           
 
         
  
where the function    specifies the amount of payment that is lost due to mortality 
experience, namely 
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    (15)    
Risk-Neutral Pricing 
    Risk-neutral pricing was used by Milevsky and Promislow (2001) and by Blake, 
Cairns, and Dowd (2006a). The method is derived from financial economic theory that is 
applicable even in an incomplete market. If the overall market has no arbitrage, then there 
exists at least one risk-neutral measure Q which can be used for calculating fair prices. 
We apply the approach in Blake, Cairns, and Dowd (2006b), which assumes the market 
price of mortality risk is constant and estimates it from the Swiss Mortality Bond. As a 
more liquid mortality linked securities market develops, a more accurate market price of 
risk can be calculated based on the adequacy of deals and data. 
    The payoff of the longevity derivative instrument that we consider in this paper 
is dependent on the difference between the experienced and expected mortality (or 
equivalently, survival) rate. However, the mortality rate in our model for a fixed age is 
itself linearly dependent on the time series   , that we modeled using the DEJD. In an 
incomplete market, the risk neutral pricing will allow pricing of the derivative. Kou and 
Wang (2004) have discussed derivative pricing using the DEJD model for security prices, 
and they have derived the risk neutral measure for this stochastic process. Using their 
results, the DEJD model in the physical measure has a risk neutral DEJD model with 
parameters given below where the asterisk symbol * denotes that the parameter 
corresponds to the risk neutral measure: 
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    We may integrate (16) to obtain 
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 According to Kou and Wang (2004) the characteristic function is 
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Using    for θ in (19), the closed-form expression for the expected future 
mortality rate      is derived as  
                  
                       
      
                    
  
 
 
          
 
 
  
          
    
 
  
   
 
    
 
  
   
     (21) 
 Formula (20) can be used to calculate the expected future mortality rate directly 
with parameters {        
    
       }, which is much faster and more convenient than 
using simulation to project and average the paths of future mortality rates. This model is 
especially suitable for pricing the mortality linked securities whose cash flow each period 
is a linear function of the mortality rate (e.g., the q-forward). We will discuss the example 
of q-forward pricing in section 4.4. 
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We can derive the implied market price of risk   based on the actively traded 
mortality linked securities on the market whose fair price is already known, and then 
apply the same   to price the unknown mortality linked securities. In the previous 
research, the annuity price (Cox and Lin, 2006) or the mortality bond price (Chen and 
Cox, 2009), was used as the known traded price. In this paper, we use the Swiss Re 
mortality catastrophe bond to determine a known market price of mortality risk to enable 
us to calculate  , and then use this in our DEJD model to price the q-forward 
incorporating   as an implementation example of our DEJD model. For comparison 
purposes, we consider three possible models corresponding to the Brownian motion, the 
positive jump severity and the negative jump severity, along with       
    
  . Since the 
mortality linked securities are priced in an existing incomplete market, the value of   or 
the risk-neutral measure Q is not unique. Practically speaking we have only one mortality 
linked security to use (the Swiss Re Bond) but need to calculate three market prices of 
risk. Accordingly we use the process suggested by Blake, Cairns, and Dowd, (2006b), to 
estimate the set of   by sequentially changing one and fixing the rest. 
Consider the market prices of risk set              with  
      ; 
  
         and   
       . We can then estimate the components of   by 
changing only one and fixing the rest. The algorithm below is similar to the traditional 
procedure for calculating the market price of risk with Wang transform approach (Chen 
and Cox, 2009): 
Step 1. Based on the known 2003 mortality time-series, simulate 10,000 times the 
future mortality time-series      for 2004-2006, using the DEJD model (7) with the 
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calibrated parameter set                 ={0.064, 0.45; 0.71, 0.75; -0.20, 0.31}, and 
the initial assumed set                     , with the risk-neutral transform function. 
Step 2. Calculate the mortality rate      by the formula (4) and calculate the 
average    based on year 2000 standard population and corresponding weights. The year 
2000 standard population and corresponding weights is based on the technique notes of 
the NCHS report GMWK293R. The weights are 0.013818 for the (<1) age group, 
0.055317 for the (1--4) age group, 0.145565 for the (5--14) age group, 0.138646 for the 
(15--24) age group, 0.135573 for the (25--34) age group, 0.162613 for  the(35--44) age 
group, 0.134834 for the (45--54) age group, 0.087247 for the (55--64) age group, 
0.066037 for the (65--74) age group, 0.044842 for the (75--84) age group, and 0.015508 
for the (>85) age group. These are tabulated in Table 10. 
Step 3. Calculate the expected value of the principal payment in every period T  
by the formula,   
                                     
    
        , where    
is given by (15). The coupon payment in every period is calculated based on the par 
spread plus 135 basis points, the latter of which was obtained by reference to the risk 
premium of the Swiss Re Mortality Bond Contract. 
Step 4. Iteratively adjust the market price of risk set  , and repeat step.1-step.3 
until the discounted expected value of the coupon payment in 2004-2006 plus the 
principal payment in 2006 equals the face value of the mortality bond $400,000,000. 
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Table 7 Implied Market Prices of Risk by Risk-Neutral Approach 
 
 
  
 
  
 
 
6.15 0 0 
0 0.21 0 
0 0.18 0.18 
 
Wang Transform: 
We do not have efficiently traded underlying mortality index to create a 
replicating portfolio for pricing. In such an incomplete market situation, Wang (2002) 
develops a method for pricing risks which combines financial and insurance pricing 
theories. Wang's distorted method transforms the underlying distribution to enable the 
securities price to exactly equal the discounted expected values. Wang's transform is 
intuitive finance theory since it is in accordance with the capital asset pricing model 
(CAPM) for underlying assets and the Black-Scholes formula for options. Wang's 
transform is practical and can be easily applied in calculation. 
Given a random payment X and cumulative density function       under the 
measure P, then the Wang Transform is defined as that the "distorted" or transformed 
distribution   
     is determined by the market price of risk δ according to the equation 
                                           
                                       (22) 
where Φ(x) is the standard normal cdf, and δ is the implied market price of risk which 
reflects the level of market systematic unhedgeable risk. After the transform, the fair 
price of X, or the expectation of X under   
     should be the discounted expected value 
using the transformed distribution. 
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We can derive the implied market price of risk δ based on the actively traded 
mortality linked securities on the market whose fair price is already known, and then 
apply the same δ to price the unknown mortality linked securities. In the previous 
research, annuity (Cox and Lin, 2006) or the mortality bond (Chen and Cox, 2009), is 
applied as the known traded price. In this paper, we use Swiss Re mortality catastrophe 
bond as the known price to calculate δ, then to price the q-forward as an implementation 
example of our DEJD model. The set of implied market price of risk              is 
in correspondance to the Brownian motion, the positve jump scale and the negative jump 
scale,       
    
  . Since the mortality linked securities are priced in the incomplete 
market, the value of δ or the risk-neutral measure Q is not unique. We have only one 
mortality linked security but need to calculate four market prices of risk. Following 
(Cairns, Blake, and Dowd, 2006b), we can estimate set of δ by changing one and fixing 
the rest. 
Following is the traditional procedure for calculating the market price of risk 
(Chen and Cox, 2009): 
Step 1. Based on the known 2003 mortality indicator, simulate 10,000 times the 
future mortality indicator      for 2004-2006, using the DEJD model (7) with the 
calibrated parameter set                 ={0.064, 0.45; 0.71, 0.75; -0.20, 0.31}, and 
the initial assumed set             , with Wang Transform function. 
Step 2. Calculate the mortality rate      by the formula (4) and calculate the 
average    based on year 2000 standard population and corresponding weights. 
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Step 3. Calculate expected value of the principal payment in every period T by the 
formula,   
                                     
    
         ,    follows 
(15). The coupon payment in every period is calculated based on the par spread plus 
1.35% risk premium. 
Step 4. Adjust the market price of risk set δ, and repeat step.1-step.3 until the 
discounted expected value of the coupon payment in 2004-2006 plus the principal 
payment in 2006 equal the face value of the mortality bond $400,000,000. 
Table 8 Implied Market Prices of Risk by Wang Transform 
         
6.15 0 0 
0 1.82 0 
0 1.79 1.79 
 
The value of    and    are the same for the risk neutral approach and the wang 
transform, which are correspondance to the drift of the Brownian Motion. The value of 
(  ,   ) (  ,   ) are different since the approaches for the implied market price of risk 
are different. 
3.5 EXAMPLE: Q-FORWARD PRICING 
JP Morgan proposed q-forwards derivative contracts as simple capital markets 
instrument for transferring longevity and mortality risk. q-forwards enable pension funds 
to hedge against increasing life expectancy of plan members and life insurers to protect 
themselves against significant increases in the mortality of policyholders. Similar in 
structure to other forwards, q-forwards are securities involving the exchange of the 
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realized mortality of a population at some future date, in return for a fixed mortality rate 
agreed at inception. Theses q-forwards can provide the basic building blocks from which 
many other complex mortality/longevity risk securities can be constructed. A q-forward 
provides a type of standardized contract which could help to create a liquid longevity risk 
capital market. A set of q-forwards that settle based on the LifeMetrics Mortality Index 
(JP Morgan, 2007) could fulfill this role. Since the counterparty who is not exposed to the 
longevity risk requires a risk premium to take on longevity risk, the mortality forward 
rates at which q-forwards transact will be below the expected, or "best estimate" 
mortality rates The standard actuarial notation uses   for mortality rate, and this is how 
q-forward derivative is named. In our notation,   is denoted by  . 
 
Figure 10 Longevity Risk Hedge and Mortality Risk Hedge 
 
A q-forward type contract that can be used by a life insurer to hedge mortality risk 
occurs when the life insurer pays the fixed mortality rate to the investment bank and the 
investment bank pays the realized mortality rate to the life insurer. The life insurer 
receives the payment                                         , as shown in 
Table 9. When the realized mortality rate increases, the investment bank pays more (the 
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realized rate minus the fixed rate) to the life insurer which offsets the loss incurred by the 
life insurer due to the experienced increase in mortality. A q-forward type contract can 
also be used by a pension fund or by Social Security to hedge longevity risk. The pension 
fund pays the realized mortality rate to the investment bank and the investment bank pays 
the fixed rate to the pension fund. The pension fund receives the payment 
                                        . When the mortality decreases 
(longevity increases), the investment bank pays more (fixed rate minus realized rate) to 
the pension fund which can then use these funds to cover the loss incurred by the pension 
fund due to the experienced increase in longevity. In this way, pension funds that are long 
on longevity risk can transfer the risk to investors who are willing to take on this extra 
risk for the increased return they receive. Similarly, life insurers who are long on 
mortality risk can transfer the risk to investors who want to short the mortality risk3. Of 
course the pension fund and the life insurer are natural counterparties, and the investment 
bank can serve as a financial intermediary facilitating their mutual hedging as in Figure 
10. 
 
 
 
                                                 
3 Of course investors can take either side of the transaction, they do not need to go long or short as 
described above, only take the side they view as advantageous. 
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Table 9 Example of q-Forward Structure 
Notional Amount $ 50,000,000 
Trade Date 31 Dec. 2006 
Effective Date 31 Dec. 2006 
Maturity Date 31 Dec. 2016 
Reference Year 2015 
Fixed Rate        0.8765% (or 87.65 basis points) 
Fixed Rate Payer XYZ Investment Bank 
Fixed Amount Notional Amount × Fixed Rate × 100 
Reference Rate LifeMetrics Index 
Floating Amount Payer XYZ Pension or Annuity Provider 
Floating Amount Notional Amount × Reference Rate × 100 
Settlement Net settlement = Fixed amount - Floating amount 
Based on our DEJD model and the q-forwards product structure above, the fixed 
rate can be calculated with the closed-form formula (21) directly. 
           
 
          
             
    
 
                    
  
 
 
          
  
 
 
  
          
    
 
  
   
 
    
 
  
   
      
In our context, the Fixed Rate        is represented as  
       , the expected 
future mortality rate in the risk neutral measure with    being a weight associated with 
the age category. These weights are given in Table 10. 
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 Table 10 Parameters for the Closed-Form Solution of the q-Forward4 
Age-specific 
Parameters 
          Other  
Parameters 
Parameters 
Value 
<1 0.013818 -3.4087 0.1455     -10.302 
1-4 0.055317 -6.2254 0.1960    10 
5-14 0.145565 -7.1976 0.1492     -0.20 
15-24 0.138646 -6.2957 0.0994     0.31 
25-34 0.135573 -5.9923 0.1044     0.029 
35-44 0.162613 -5.4819 0.0855     -1.25 
45-54 0.134834 -4.7799 0.0608     0.035 
55-64 0.087247 -4.0137 0.0468    
  0.89 
65-74 0.066037 -3.2347 0.0426     0.065 
75-84 0.044842 -2.4196 0.0409    
  0.93 
>85 0.015508 -1.6119 0.0290    
The fixed rate or equivalently the mortality forward rate quoted by an investment 
bank would be formed using a combination of (i). best estimate mortality projection, (ii). 
a risk premium, and (iii). mid-to-bid spread (half of the ask-bid spread). 
The best estimate of mortality will depend on the model used, e.g., the Lee-Carter 
model, and so may be biased if the model is not the most appropriate one. The risk 
premium must also be appropriate for the market and based on transactions there. 
Unfortunately to date, there are very few transactions involving mortality based 
derivatives and so the risk premium calculation in this market is currently problematic. 
The calculation presented here uses the well known risk neutral valuation 
approach with adjustments for mortality and longevity jumps. The jump processes play a 
role in fitting the data and in estimating the risk premium. The mortality forward rate 
                                                 
4 We apply the risk-neutral measure change on the positive jump severity   
  and negative jump 
severity   
 . 
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flows from the closed-form solution. For the U.S. data used here, the fixed rate 10 year q-
forward contract is priced at 0.8765% (or 87.65 basis points). This DEJD pricing may 
differ from that of the Lee-Carter or Chen-Cox models. 
The Lee-Carter model, the Chen-Cox model and our DEJD model will naturally 
yield different values for the best estimate mortality projection. Not incorporating the 
asymmetric jump effect will make a difference in the calculated expected mortality rate 
that enters into the determination of the fixed rate payment component of the swap in 
Figure 10. Using the same data, whole age groups, and both sexes in the reference year 
for the U.S. national population, the result for the best estimate mortality projection for q-
forward fixed rate is 0.8583% using the Lee-Carter model, 0.8594% using the Chen-Cox 
model, and 0.8765% using the DEJD model. Thus, the DEJD model will yield a larger 
expected fixed payment affecting the size of the experienced swap. 
The Lee-Carter model captures the significant positive jump (1918 flu) and 
moderate negative jump in the baseline Brownian motion process, which caused a larger 
standard deviation and a positively biased mean for the baseline Brownian motion 
process. If we set the Lee-Carter model as the benchmark and compare the Chen-Cox 
model and the DEJD models, we conclude the following. 
Compared to the Lee-Carter model, the Chen-Cox model considers the significant 
positive jump and moderate negative jump in the normal jump process, not in the 
baseline Brownian motion process. This reduces the standard deviation and the mean in 
the baseline Brownian motion process. However, in the projection of future mortality 
rates, the jumps are assumed to occur symmetrically in the jump diffusion model of the 
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Chen-Cox model, so the overall jump effects offset each other (positive and negative). 
The jump diffusion doesn't affect the mean of the Brownian motion process by very 
much, so the pricing of the fixed rate is not much different from that obtained with the 
Lee-Carter model. 
Compared to the Lee-Carter model, our DEJD model considers the possibility of 
both positive jumps and negative jumps in the jump diffusion process, not in the baseline 
Brownian motion process. This also reduces the standard deviation and the mean in 
comparison with the baseline Brownian motion process. The difference of the DEJD 
model from the Chen-Cox model is that, in the projection of the future mortality rate, the 
jumps in the DEJD model are assumed to occur asymmetrically following the historical 
rule of infrequent significant positive jumps and more frequent moderate negative jumps. 
In this way, the overall jump effect adds a positive increment to the mean of Brownian 
motion process, which causes the pricing of the fixed rate to be higher than that obtained 
with the Lee-Carter model. 
Some final comments about the q-forward prices developed in this paper are in 
order. A pricing difference in the q-forward also can arise from the use of a different 
implied market price of risk. Due to the lack of a sufficient number of mortality securities 
in the market, the implied market price of risk used in this article in conjunction with our 
model was estimated using only one product, i.e., the Swiss Re mortality catastrophe 
bond. Applying a different estimated implied market price of risk in the formula will 
cause a difference in the quoted q-forward fixed rate. Also, in realistic deals, the mid-bid 
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spread (defined as the half of the bid-ask spread), and other factors including judgment 
calls can also cause a difference in the quoted fixed rate of q-forward. 
3.6 CONCLUSION 
This paper proposed a quantitative model to price mortality-linked securities, and 
provided a possible approach to measuring and managing longevity/mortality risk. 
Marked improvement in life expectancy has attracted public attention to the financial 
consequences of longevity risk on pension plans, long term care insurance, and Social 
Security solvency. Longevity risk can also seriously affect the asset and liability balance 
of the pension fund and annuity providers. On the other side of the longevity/mortality 
market, life insurers have begun to show increased concern about increased mortality risk 
caused, for example, by sudden influenza or other natural or man-made catastrophic 
sources. A series of mortality linked securities, e.g. longevity bond, mortality bond, and 
other types of securities have been issued to manage and transfer the risk. Additionally, 
the recent market involving life settlement securitization whose pricing depends on 
modeling the life expectancy of insurance policy holders has boomed. Hence, modeling 
and pricing mortality linked securities is crucial to risk management, product innovation 
and formation of a liquid intermediate market. 
This paper proposed a stochastic mortality model to capture the observed feature 
of the historical mortality rate process, and used this model to price mortality linked 
securities. The baseline component of our model incorporates the advantages of the Lee-
Carter framework, which describes the main trend and regular dynamics of historical 
mortality rate and is able to adjust for the cohort effect. The jump diffusion component in 
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our model applies the compound Poisson-double exponential jump diffusion to extend 
the Lee Carter model so as to describe longevity jumps (negative jumps) and mortality 
jumps (positive jumps) separately. Our model accommodates the different features of 
longevity jumps and mortality jumps. Hence the model fits the mortality time-series 
increment distribution much better than the previous models and explains the distribution 
skewness effect. In addition, our proposed model has an advantage of mathematical 
tractability and the ability to obtain a closed-form solution for the standard securities, like 
the q-forward contract, whose price depends on the expected future mortality rate. Since 
the DEJD model has the concise specification and closed-form density function, the 
likelihood function for the parameters can be easily expressed. In this way, the small 
number of parameters and concise likelihood function facilitates the calibration and 
application of the model in practice. 
We calibrated our model with the historical mortality rate data 1900-2004 from 
National Center for Health Statistics and we compared the prices of the q-forward fixed 
rate, calculated by the Lee-Carter model, the Chen-Cox model and our DEJD model. We 
found that our mortality model fits this data better and that the q-forward fixed rate in the 
contracted swap used for hedging longevity risk is higher from our model. 
As a caveat, however, should note that we use only 104 years of recent data, and 
the last 104 years may not be the same as the next 104 year (technological innovations 
are occurring more rapidly now than in the past). Moreover, 104 years may not be 
adequate for modeling certain low frequency events. Can a 1918 flu epidemic scale event 
be expected once every 100 years or once every 200 years? Also, the fact that large 
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longevity jumps have not occurred within this data set does not mean they have not 
occurred in the past (the acceptance of the germ theory of disease prior to this data set, 
for example) or that they will not occur in the future. Cox, Lin and Pedersen (2010) note 
that some experts conjecture that we may experience extreme events of both types in the 
future. As with all actuarial modeling, have to accept that there is a real risk that the 
coefficients we estimate may prove to be incorrect if the past data is not reflective of the 
future. Model risk is always an actuarial issue, and our mortality model is no exception. 
For the creation of capital market financial instruments to hedge longevity risk such as in 
Figure 10, however, the model risk does not affect the hedger (the pension fund's hedge 
still works and the life insurer's hedge still works), and the investment bank intermediary 
is protected as long as they did not take a long or short position. Thus, while model risk is 
an important concern as far as mortality modeling is concerned, it is of less concern in the 
dual hedging context of this paper. 
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Chapter 4 Longevity Risk in Life Settlement Products Pricing 
4.1 INTRODUCTION 
While the effect of longevity risk is traditionally thought of in terms of its impact 
on pensions, social security systems and corporate defined benefit plan solvency, there is 
another market that is vulnerable to longevity risk, perhaps more than the above, namely 
the life settlement (and securitization) market. A life settlement is a financial arrangement 
whereby the third party (or investor) purchases a life insurance policy from the person 
who originally purchased the life insurance policy. This third party pays the insured an 
amount greater than the cash surrender value of the policy -- in effect, the trade-in value 
of the policy as determined by the originating insurance company5 -- but less than the 
face value (or the death benefit). They do this in exchange for the right to collect the 
death benefit upon the death of the insured. The investor also agrees to make the future 
life insurance premium payments until the death of the insured. It can be a win-win 
situation, as the investor can obtain a return on their initial investment and premium 
payments once the death benefit becomes payable (assuming the insured does not live too 
much longer than expected when setting the purchase price) and the owner of the policy 
obtains more money than they would if they had surrendered the policy for its cash value 
or allowed it to lapse. The win-win situation is for the contract participants (the insured 
and the life settlement investor). Other third parties may have losses due to this 
transaction, however. The insurer, for example, loses the ability to recapture the policy 
                                                 
5 The cash value of the policy is also known as the non-forfeiture value since this is the least amount the 
insurer can pay to a surrendering policy holder. Formula for calculating the cash value can be found in 
Bowers et al (1997), Actuarial Mathematics. 
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value upon lapse by the policy owner. The losses of recaptured lapse value by the insurer 
may also cause the insurer to have to raise premiums to future customers if the recaptured 
lapse value becomes significant due to a significant growth in life settlements (unless the 
insurer itself enters the life settlement market to capture the otherwise lost profit, or to 
use a life settlement portfolio as a natural hedge against longevity risk for their own life 
insurance book of business). This market has grown. According to Annin, DeMars, and 
Morrow (2010 p. 1); "It is estimated that in the past five years alone, more than $40 
billion of the face value has been sold in the life settlement market."  
In this market, there is a vulnerability to longevity risk as increased longevity 
implies longer periods of investors paying premiums prior to collecting their money, and 
hence the potential for losing money or going bankruptcy. The rise and fall of the viatical 
settlement market, where the life settlement market arose, illustrates these dangers and 
susceptibility to increases in longevity. 
The practice of buying and selling of "viatical settlements" began in the late 
1980s when the AIDS epidemic presented a devastating medical shock to thousands of 
previously healthy Americans (Stone and Zissu 2006). Due to the extremely high medical 
costs associated with treatments for this disease and the difficulty for too-ill-to-work HIV 
positive individuals to sustain an active income, many AIDS patients and their families 
became financially vulnerable. Thus, a market developed to relieve some of the monetary 
stress of AIDS victims. 
  Seen as a new opportunity, investors (predominately entrepreneurs) stepped in 
and offered to buy AIDS patients' life insurance policies for a price less than their face 
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value. The investors would take over the premium payments---also a burden the 
terminally ill found too heavy to carry with deteriorating health---and become the 
beneficiary of the policy when a certain "waiting period" had passed. Then, once the 
insured died, the investor would obtain the proceeds of the life insurance policy. Since 
these patients were given very little time left to live (typically two to three years), the 
investor would not have to pay many premiums, and after subtracting the initial payment 
to the insured and subsequent premiums from the final payout of the life insurance 
policy, the investor would theoretically end up with a large profit (Quinn 2008). 
  As the success of viatical settlement investments went public, the market for such 
investments grew and companies were created that specialized in fulfilling investors' 
desires for viatical settlements. It was not much later, however, that this new market 
collapsed due to a change in the longevity risk. At the 1996 International AIDS 
Conference in Vancouver, papers were presented that gave evidence of a new drug 
capable of substantially reducing, perhaps even to zero, the level of HIV in its infectees. 
This research had a twofold impact: On one hand, it offered new hope for increased life 
to the AIDS infected community but, on the other hand, this sudden increase in longevity 
pronounced a death sentence to firms that had been surviving off profits from the sale of 
viatical settlements. The second effect is evident in the collapsed value of the viatical 
settlement firm, Dignity Partner, and the significant decrease in prices being offered to 
AIDS victims for their insurance policies. As evidence grew that policies might take a 
substantially longer time to mature, their value plummeted (Stone and Zissu 2006). 
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As the viatical settlements market collapsed, investment companies, in order to 
keep the life settlement backed securities market alive, expanded their life insurance 
purchases to those belonging to the elderly. Companies selected elderly people with 
estimated low life expectancies because a low life expectancy meant a greater possibility 
of profiting sooner from the purchase of life insurance policies. Today, this life 
settlement market has a growing potential as the baby boomers are now entering old age. 
As the population ages, funding retirement over the last few years of life becomes an 
escalating concern. Life settlements for senior citizens have become popular, partly due 
to the extensive marketing pursued by life settlement companies. The senior market now 
comprises about 80% of the entire viatical and life settlements industry (ViaticalWeb 
2011). Moreover this market may continue to grow. Due to gradual increases in 
technology and beneficial medical treatment in the United States, the number of 
centenarians (individuals over the age of 100) has increased from 15,000 in 1980 to 
roughly 72,000 in 2000 and the number is predicted by the Social Security Advisory 
Board to reach to 4.2 million, (or approximately 1% of the projected total population) by 
2050 (Scotti and Effenberger, 2007). 
The life settlement market has developed at a rapid pace in its early years. Two 
recent surveys estimate that the available market size will grow from $13 billion in 2004 
to $161 billion over the next few decades through a combination of population aging, 
increasing life expectancy and increasing market penetration. Life settlement has 
attracted a broad range of attention, including dominant investment banks and major 
reinsurance companies as intermediaries, the Securities and Exchange Commission 
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(SEC), the National Association of Insurance Commissioners (NAIC) and National 
Conference of Insurance Legislators (NCOIL), as well as, state regulators and other 
rating agents and life expectancy underwriters. 
However, just as advancements in treating AIDS led the viatical settlement 
market to succumb to longevity risk, the substantial increases in longevity during the 20th 
and 21st centuries can pose substantial risks to the current life settlement market. A large 
longevity jump could occur in the future if an effective treatment of coronary heart 
disease or cancer is found, as these two causes of death combined constitute more than 
half of all deaths among people over the age of 40 (Johnson, Bengtson and Coleman 2005 
p. 109). Thus, the modeling of longevity risk is of potentially more important in the life 
settlements market than it is in the pension market because the life settlement market is 
based (and funded) on shorter horizons.  
Very little literature has discussed the issue of determining a pricing model for 
life settlement portfolios subject to jump discontinuities between mortality and longevity. 
The main factor in the life settlement securities pricing currently is the estimation of the 
life expectancy of the insured. Incorporating longevity risk into the pricing structure 
when evaluating life settlement securities turns out to be more complicated. 
In this paper, I propose a Whole Life Time Distribution Dynamic Pricing 
(WLTDDP) method to evaluate the life settlement products. The method determines the 
life expectancy and generates a life table for different birth year cohorts with potential 
jump discontinuities in both mortality and in longevity rates. The method incorporates the 
updated information on the individual insured’s life expectancy (obtained from an expert 
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medical underwriter), which is a critical factor that enters into the evaluation of the life 
settlement products.  
In past life settlement transactions, the life expectancy of the insured was 
considered as the most critical (often the only) variable used in determining the sales 
price of the policy as this represents the expected life length of the insured when he or 
she sells the life insurance policy to the third party as a life settlement (the time to 
payment for the investor). Essentially, if T represents the (random) future life of the 
insured, then the life expectancy is       .  This life expectancy is computed using 
an appropriate life table, or in the case of life settlements, is usually given by a medical 
expert based on their examination of the current medical record of the insured.  If the 
discount factor is           where   denotes the required rate of return, then the 
current value of the pay off of a life insurance policy with a benefit of $B is traditionally 
calculated as    . However, this is a systematically biased assessment of the value of 
the payoff and leads to a systematically inaccurate evaluation of the value of the life 
settlement product.  
According to Jensen’s inequality, if f is any convex function, and X is any random 
variable, then                . In the current situation we             )) 
with      to observe      , so   is convex. According to Jensen’s inequality, if 
     is convex, and     denotes the life length of the insured, then             
which means the expected value of the discounted benefit is always greater than the 
benefit discounted by the expected time to death. Thus the traditional evaluation of the 
present value of the life insurance payoff using the life expectation alone as in        
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systematically underestimates the true expected payoff of       . This results in a 
negatively biased price to the insured policyholder. Note that this bias may be 
intentionally used as a mechanism to increase profitability by the purchaser or to hedge 
against adverse selection or longevity risk. While this bias in always present regardless of 
the probability distribution used for  , the appropriate distribution is also necessary for a 
correct assessment of the actual expected net present value of the benefit payment in the 
life settlement, namely       . 
In the past, life expectancy was considered in the pricing as a solo variable 
representing the expected life time of the insured when he sells his life insurance policy 
to the third party as a life settlement. However, this is an inaccurate approach to evaluate 
the life settlement product. According to Jensen’s inequality, the value of life settlement 
products are contingent on the expected value of the functions of life time, which is 
always larger than the value of the function of the expected life time (or life expectancy). 
So, the previous pricing method based on life expectancy has a negative bias for pricing 
the life settlement products. In order to solve this problem, we need to generate the whole 
distribution for the life time.   
The advantage of Whole Life Time Distribution Dynamic Pricing (WLTDDP) 
method is that it generates a complete life table with the whole distribution of life time 
instead of the expected life time (life expectancy). In this way, the method provides a 
more accurate projection and evaluation for the life settlement products, through 
incorporating more statistical information of the insured’s future life time. The statistical 
methodology is based on information theory for adjusting mortality tables to obtain 
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exactly some known individual characteristics while obtaining a table that is as close as 
possible to a standard one.  
Another advantage of WLTDDP is that it incorporates the effect of the dynamic 
longevity risk through the original life table which is generated from the Double 
Exponential Jump Diffusion model (DEJD) (Deng, Brockett and MacMinn 2010). The 
DEJD model incorporates the longevity jump (caused by medical improvement, etc), 
mortality jump (caused by pandemic influenza, etc) and dynamic main trend of the 
mortality rate which provide a better explanation and fit to the historical mortality rate 
data. The longevity jump or mortality jump can seriously distort the features of the 
mortality rate trend and affect the evaluation of the life settlement products which is 
contingent on the mortality rate and life expectancy. This model is an extension of the 
Lee-Carter Mortality model which differentiates age and cohort effects. It incorporates a 
Brownian motion process for smooth mortality changes plus an asymmetric jump 
diffusion process allowing for jumps up or down in the mortality rate in the critical 
temporal mortality process. This model is used for the estimation and forecasting of 
mortality rates and life expectancy and ultimately the pricing of the individual life 
settlement. The life table projected by the DEJD model incorporates the features of the 
historical mortality trend and the longevity risk and it provides a more accurate base for 
pricing life settlement products. 
The life settlements literature does not allow jumps in longevity (such as those 
that destroyed the viatical settlements market), so this paper will be the first to allow for 
such jumps while still having uncertainty in the possibility of such jumps occurring. 
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Additionally, jumps in mortality (as opposed to longevity) may also occur (such as an 
infectious disease which differentially impacts vulnerable elderly populations) and this is 
allowed when using the DEJD model for pricing. Increased mortality would cause an 
increase in the value of the life settlement to the investor. Currently, jump changes that 
increase or decrease the expected mortality rate are not incorporated in previous models. 
Jumps are important sources of return uncertainty in life settlement investments, which is 
the reason they are used in my model. Finally, as population longevity increases, 
especially among the very old, the usefulness to individuals of using life settlements to 
obtain additional money in their old age could attract more individuals and proper pricing 
using the DEJD model may have a social benefit, as well as, the more rational pricing 
developed here. 
4.2 DESCRIPTION OF THE LIFE SETTLEMENT MARKET 
The life settlement market developed rapidly in its early years. The face amount 
of life insurance settled was estimated at $10 billion at 2005, and this continued to grow 
to $12 billion in 2007. Similar to other financial product markets, the life settlement 
market experienced a contraction during 2008 and the face amount was estimated at 
$11.7 billion in 2008. (Conning Research, Oct. 8, 2008, Life settlements: New challenges 
to growth.) Two recent surveys have estimated that the available market size will grow 
from $13 billion in 2004 to $161 billion over the next few decades, through a 
combination of population aging, increasing life expectancy and increasing market 
penetration of life settlement options available to policy holders (Bernstein Research 
2005, 2006). Life settlement as an investment asset class has attracted a broad range of 
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attention, including dominant investment banks and major reinsurance companies as 
intermediaries, the Securities and Exchange Commission (SEC), National Association of 
Insurance Commissioners (NAIC) and National Conference of Insurance Legislators 
(NCOIL) as regulators, and other rating agents and life expectancy underwriters as 
participant information suppliers. 
Before the life settlement market emerged, if a policy owner no longer wanted, 
needed, or could not afford to pay the premiums for a life insurance policy they had 
limited choices.  They could cash out a policy by surrendering the policy to the 
insurance company to receive the surrender value or they could simply stop making 
premium payments and allow the policy to lapse. In most cases, the policy would be 
worth considerably more than the surrender value making it an unattractive option. The 
surrender value is based on the commissioner’s standard ordinary (CSO) mortality tables, 
in force at the time the policy was issued and usually many years prior to the decision to 
surrender. These are smooth mortality tables used for conservative non-forfeiture value 
calculations and do not anticipate health changes in individuals but only in the aggregate 
group and are the basis for the table construction. Later on, after health changes, another 
mortality table may more accurately reflect the anticipated mortality probabilities of an 
individual insured. The cash value calculation is incorporated as part of the insurance 
contract and is not negotiable.  Lapsing the policy forfeits (or slowly runs out) the cash 
value in most cases.  Under either choice scenario, the extra value in an unwanted or 
unneeded policy was relinquished back to the life insurance company who issued the 
policy and not captured by the insured.  
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A life settlement provides a secondary financial market for this contingent claims 
contract producing an alternative option to the policy holder other than the surrender or 
lapse of a policy. In this way, the policy holder can gain the extra value inherent in the 
policy instead of giving it back to the insurer. When the owner of a life insurance policy 
no longer needs or wants the policy, the policy is underperforming or the he can no 
longer afford to pay the premiums, he should have the right to resell the policy to the 
third party for the highest payment. 
Several market intermediaries play a role in the accomplishment of the life 
settlement, including insured individuals (or policy owners), producers (financial 
advisors or insurance agents), settlement brokers (insurance agents), life expectancy 
underwriters (who evaluate the life expectancy of the underlying insured life at the time 
of sale), providers (parties acquiring the policy and paying the insured for the right to 
claim the life insurance benefits), and investors (who either bundle collections of life 
settlements and securitize them for resale, or keep them for investment purposes as a new 
asset class in their own portfolio). The majority of investors in today's life settlement 
market are large institutional investors seeking to acquire large pools of policies. Retail 
investors also participate in the life settlement market, generally by purchasing fractional 
interests in settled policies. To the investor, the life settlement portfolio provides an 
essentially zero-beta asset which can help diversify a larger portfolio of financial market 
sensitive assets6. 
                                                 
6 It can also be used as a zero beta asset for valuation of portfolios in a Black type Capital Asset Portfolio 
Model instead of the Market portfolio which has well known identifiably problems since Roll’s criticism of 
the CAPM. (Black, et al., 1972),(Roll, R., 1977). 
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Most insured policy holders participating in the life settlement market are seniors 
with a life expectancy of more than two years. The process or procedures involved in the 
life settlement transaction transpire as follows: 
1. Insured individuals or policy owners initiate the process to contact a producer (usually 
financial advisors or insurance agents). Sometimes the producer contacts the insured 
because they know the insured has a need for the sale of their life insurance policy. 
2. The producer contacts one (or usually more than one) life settlement broker with a 
license to do business in life settlements in the policy holders’ state of residence 
(insurance is a regulated industry). 
3. The settlement broker(s) collects the medical information concerning the current health 
status of the policy holder and “settles” the policy by contacting life expectancy 
underwriters. 
4. The contacted life expectancy underwriters are responsible for preparing a life 
expectancy assessment and evaluating the mortality risk of the insured based on the 
current health information provided by the settlement broker. 
5. Providers review the data on policy terms, life expectancy, premium amounts, and bid 
on the amount they would be willing to pay the insured policy owner to take over 
premium payments in return for collecting the ultimate life insurance benefit upon the 
death of the insured.  This bid is based on supplied information and settlement 
applications prepared by settlement brokers. 
6. The existing insured elects to either hold (not sell on the secondary market) or to sell 
their policy.  This can then be held in a portfolio or resold into a life settlement 
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securitization issue which expands the asset class to the broader class of investors with 
interests in life settlements. 
Pricing of the life settlement securities depends on the estimation and forecast of 
mortality rates or life expectancy, which are considerations involving mortality risk and 
longevity risk. In this paper, I apply the DEJD stochastic mortality model (Deng, et al, 
2010) to model mortality underlying the life settlement securities. The model is based on 
the Brownian motion process, plus an asymmetric jump diffusion process for the 
estimation and forecasting of mortality rates and life expectancy. 
4.3 THE STOCHASTIC MORTALITY MODEL SPECIFICATION 
To capture the features of the mortality time-series    and to account for the 
tractability and the calibration of the model, we set the model specification to describe  
    in the approximate continuous-time model of      as given below. 
The dynamics of the mortality time-series     is specified as: 
                       
    
   
 
where    is a standard Brownian motion,      is a Poisson process with rate  , where 
  describes the expected frequency of the jumps. The larger the  , the more times jumps 
occur in the mortality time-series. Here    is a sequence of independent identically 
distributed (   ) nonnegative random variables,           has a double exponential 
distribution with the density: 
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The parameters   and   represent respectively, the proportion of positive jumps 
and negative jumps among all jumps. Thus,    is the expected frequency of positive 
jumps and    is the expected frequency of negative jumps. The parameters    and    
describe the positive jump size or severity and the negative jump size or severity 
respectively. Thus,       is exponentially distributed with mean   
  , while -Y|Y≤
0 is exponentially distributed with mean   
  . The larger   , the smaller the positive 
jump severity. Similarly, the larger    the smaller the negative jump in absolute value. 
In this way, the positive jumps and negative jumps are captured by similar distributions 
but with different parameters based on the asymmetry of jumps in the mortality time-
series    and the leptokurtic feature of    . 
The model specification with the double-exponential distribution has the advantage 
of mathematical tractability allowing a closed-form formula for the expected future 
mortality rate to be derived. Because of this closed form solution, the DEJD model may 
provide a useful stochastic mortality model for internal company mortality simulation, as 
well as, being useful in the capital market applications I discuss subsequently. The 
double-exponential distribution also has been widely implemented as a stock price jump-
diffusion model, for which closed-form solutions for options and other securities are 
available (Kou, 2004) (Deng, Brockett and MacMinn 2010). In these papers, the closed-
form solution for the expected future mortality rate is presented in the equation below: 
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We can observe clearly the two properties of the mortality rate trend from Figure 
11. First, in Figure 11, the downward trend indicates that the mortality rate follows a 
decreasing trend during 1900-2004 at all ages. For example, in the over 85 age group, the 
mortality rate decreases from 0.26 to 0.14, while in the younger age groups, such as 15-
24, the mortality rate decreases from 0.006 to 0.0008. The decreasing trend shows the 
improvement of the life times or longevity in all age groups. Second, the change in the 
mortality rate in the older-age groups is more significant with a steeper downward trend 
than that in the younger-age groups.     
Figure 11 1900-2004 Historical Mortality Rates 
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In Figure 12, we apply the DEJD model to generate the mortality rate for all the 
age groups from 2010 to 2060 with the following equation and the parameters in Table 
10.  
Figure 12 2010-2060 Projected Mortality Rates 
 
 The projected mortality rate also presents the downward trend which indicates 
that the mortality rate follows a decreasing trend during 2010-2060, at all ages. The trend 
keeps the feature of longevity in all age groups. Similar to the historical trend, the 
improvement of the mortality rate in the older-age groups is more significant with a 
steeper downward trend than that in the younger age groups. 
A life settlement usually depends on the following characteristics of the policy 
being settled:  
1. The insurance carrier  
2. The face value (or benefit)  
3. The age of the insured person  
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4. The gender of the insured person  
5. The premium 
6. The issue date  
7. The estimated life expectancy of the insured 
8. The primary diagnosis of the insured’s illnesses if the insured is in impaired 
health 
9. The bidding or asking price of the policyholder. 
Among the attributes that affect the price of the life settlement, life expectancy is 
the key factor which is difficult to forecast and to measure. Valuation of the life insurance 
is initially based on a stable life table selected at the time of policy issue, usually a 
version of the Commission Standard Ordinary Mortality Table (CSO). These tables do 
not accommodate the improvement trends and dynamics of the mortality rate. That is, 
they are smoothed (graduated) to produce aggregate fits to data and smoothed 
progressions of premiums from age to age. The overestimation of the mortality rate and 
the underestimation of the life expectancy in stable historical life tables will cause the 
underestimation of the life insurance price at future points, and will have limited 
permissible variability across individuals due to jumps. To correctly estimate the price of 
the life insurance policies at future points in time, to effect a life settlement, I adopt the 
Double Exponential Jump Diffusion model in Deng, Brockett and MacMinn (2010) to 
project the future mortality rate and the life expectancy. Given the life expectancy, we 
can estimate the price of the life settlement incorporating both expected and unexpected 
mortality changes.  
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To explain the pricing method we use, an illustrative life insurance contract 
example is set up and a life settlement contract is derived from it. The illustrative contract 
is State Farm’s whole life policy as presented in Baranoff, Brockett and Kahane (2009).   
Assume a female purchased a whole life level premium insurance contract at the 
age of 50 in 1986. The schedule of benefits and the schedule of the premiums are shown 
in Table 11 and Table 12.  The face value (or the benefit payable at death) is $50,000. 
The annual premium is $565.50. Assume that a third party wants to acquire the life 
insurance policy when the person is 70 in 2006. In the following, we provide a model to 
price the life settlement when there is information from a doctor or an underwriting 
expert concerning the life expectancy of the individual at age 70.  
While the CSO table was used to calculate the cash value and reserves for the 
policy, the most appropriate mortality table for life settlement calculations may no longer 
be this table due to various changes in longevity and the current health state of the 
individual. 
4.4 APPLICATION OF INFORMATION THEORY 
Based on information theory, I will present a statistical methodology for adjusting 
mortality tables by incorporating known individual characteristics, and the adjusted table 
is as close as possible to the original one (Brockett and Cox, 1984). 
The use of known information about an individual to adjust a standard mortality 
table to reflect the individual's underwriting characteristics is a common problem in 
actuarial science concerns. The actuary can price life contingent financial instruments 
more accurately with the adjusted table. I present a statistical approach to mortality table 
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adjustment that simultaneously adjusts survival probabilities at all ages in a consistent, 
logical manner. I obtain a life table that includes the characteristics of the standard table 
and the add-in information for adjustment. One can start with the life table and then 
systematically adjust for the particular individual characteristics that reflect expected life 
length or a 50 percent confidence interval on the life length. 
The problem is summarized as follows: In testifying as an expert witness about 
the distribution of life time and mortality rate, an actuary is asked to adjust a standard 
mortality table to obtain a table appropriate for a particular individual given the updated 
information for the life expectancy. As an expert witness on the same side as the actuary, 
a physician testifies, that the expected remaining life of the decedent at the date of an 
untimely death was   years. The actuary needs to value a life settlement based on the 
distribution of the life time which depends on the life expectancy testified by the expert 
witness (medical report). In order to do so in a manner consistent with the physician's 
testimony, the actuary must construct a mortality table which has       , where   is 
the years remaining of the decedent under normal circumstances. If the standard table 
satisfies this condition, then there is no problem. However, since this is usually not the 
case, I suppose that for the standard table,       . 
Here we show explicitly how to obtain an adjusted table that is as 
indistinguishable as possible from the standard table and that satisfies the physician's 
constraint       . 
The method I use is based on the principle of minimum discrimination 
information explained in the next section. The prototype problem of life table adjustment 
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is carried to a numerical conclusion. Since our prototype example is discrete in character, 
I phrase all the formulas for the discrete case.  
4.4.1 Minimum Discrimination Information Estimation  
Consider the problem of distinguishing between two probability densities   and 
  after observing the value t of the random variable under study. In the application 
considered here,   and   will correspond to potential densities for the survival time of 
the individual. The technique presented here, however, is applicable to other problems of 
interest to the actuary (Brockett and Cox, 1984), (Brockett, 1991), (Brockett and Song, 
1995), (Brockett, Golden and Zimmer, 1990), (Brockett, Cooper, Learner and Phillips, 
1995). 
For distinguishing between two densities   and  , the statistic               
is a sufficient statistic and represents the log odds ratio in favor of the observation having 
come from  . It can be thought of as the amount of information contained in the 
particular observation   for discriminating in favor of   over   (Kullback, 1959). In a 
long sequence of observations from  , the long-run average log odds ratio is: 
                        
    
    
           
     
     
,               (23) 
The equation reflects the expected amount of information in an observation for 
discriminating between   and  . In the statistics and engineering literature this quantity 
is called the divergence between the densities   and   and is denoted by       . It is 
not difficult to show that         , with          if and only if    . Thus, the 
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size of        is a measure of the closeness of the densities   and  . Such a global 
measure of loss of densities will be very useful for adjusting mortality tables. 
Suppose that we are given a density function  , and we wish to find another 
density   that is as close as possible to  , and that satisfies certain moment constraints, 
such as: 
            , 
                                                         , 
... 
                          …                     (24) 
… 
                                                          , 
For example, if        , then the first constraint says that the mean for   is 
known to be   . Similarly, by taking       to be unity on a certain interval and zero off 
the interval, we arrive at a constraint on the probability for that interval. This would be 
useful, for example, if one wanted to use a medical study that gives decennial survival 
probabilities, however, yearly (or more frequent) survival probabilities are required. One 
would then find a survival density that was as close as possible to a standard mortality 
table and that reflected the decennial survival rates quoted by the medical study. 
To phrase the problem mathematically, I desire to find a vector of probabilities 
            that solves the problem: 
                                                                      (25) 
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subject to the constraints (24). Here             is the vector of probabilities 
corresponding to the standard probability distribution. Brockett, Charnes and Cooper 
(1980) show that the problem (25) has a unique solution, which is: 
                                                 ,         (26) 
where the   's are constant parameters selected in such a way that the constraints (24) are 
all satisfied. They further show that the parameters    can be obtained easily as the dual 
variables in an unconstrained convex programming problem: 
                                                              (27) 
The solution to (27) can be obtained easily by any number of efficient nonlinear 
programming codes. In the following section I use the Newton-Raphson technique. 
4.4.2 Information Theoretic Life Table Adjustments 
The study of life contingencies is intrinsically a study of biostatistics. For 
example, the life expectation is the expected value of a random variable   that equals 
the integral number of years a person now aged x will live. We have     with 
probability   ,     with probability       , etc. 
According to the standard mortality table, the distribution of the random variable 
  is given by the         dimensional probability vector 
                         , where             for                         . 
Consider now the problem of finding the mortality table that is as close as 
possible to the standard table and that satisfies certain given constraints. This translates 
into finding a probability distribution                              for the random variable   
that satisifies the desired constraints. If, for example, the desired constraints involve the 
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expectation of functions such as those given above, then the density (26) is the least 
distinguishable density from   among the class of all densities satisfying the constraints. 
The physician has testified that the expectation of life for the decedent is   more 
years. Thus, the constraint set is: 
                                                                                              (28) 
 (all sums are over {0, 1, 2 . . . . .     }). Appealing to the principle of minimum 
discrimination information, we select the density   to satisfy:  
                           
subject to the constraints (28). 
We could now of course apply the result (26) directly; however, it is perhaps 
more instructive to show how to obtain the desired density directly by standard methods 
in this simple situation. Let      . The probability distributions that we are 
considering can be viewed as     vectors                        that satisfy 
          , and       . Letting    and    denote the Lagrangian 
multipliers for the equality constraints (28) allows us to replace the original problem and 
minimize the function: 
                                         
subject to                        The     first-order conditions found by 
differentiating with respect to                           and    are as follows: 
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The first     equation give                      for   = 
0, . . . ,    The last two equalities allow me to find the parameters      and   . 
Consider the function           
   . Since      , we have 
      
                     . Therefore,               Because 
            
   , we obtain: 
             
                  
           
               
                
Thus, in order to find the precise numerical value for   , we solve: 
               
or equivalently: 
 
  
            
For       We then may obtain the other parameter    through the equation: 
              After we have the two parameters    and   , we easily calculate 
the desired density       
           . 
We used Newton's method to solve 
         
  
    for      Recall that to solve 
the equation        by Newton's method, one uses the recursion relation: 
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In my case      
         
  
     and this reduces to: 
        
     
    
  
                           
      
    
                  
 
                        
 
where         
   ,            
   , and             
    
For illustrative purposes, I shall do a numerical example that is a special case of 
the above. Assume an insured purchased the life insurance policy at age 40 in 1986 and is 
age 70 in year 2006. The medical report shows the remaining expected life time is 2 
years. The insurance policy for the insured is worth $50,000 face value (death benefit). 
Details of the policy are listed in Table 11 and Table 12.  
First, I project the standard table rate of mortality    with the Double Exponential 
Jump Diffusion model (Deng, Brockett and MacMinn 2010). Mortality rate    denotes 
the probability that a person who is alive at age   will die before age    , or for a 
pool of people,    = (the number of people die between age   and age    )/ (the 
number of people alive at age  ). We use the DEJD mortality table instead of the 
standard CSO table upon where the cash value was derived in 1986. This is more 
appropriate for this purpose since the DEJD model incorporates the dynamic and 
asymmetric longevity jump and mortality jump to describe the trend of mortality rate. In 
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this way, the DEJD model considers the longevity risk in generating the morality rate and 
life table which provides more accurate projection and better fit  
Second, the standard table probability    is deduced from   ..  For a pool of 
people,    = (the number of people die between the time   and     /(the total 
number of people at time 0).                 . 
Third, the standard table survival function is calculated by        . 
Fourth, the adjusted table rate    is deduced from    by information theory.  
Fifth, the adjusted table rate     is deduced from   .     has the same 
definition as    except that     is calculated based on the updated information.  
Sixth, the adjusted table survival function   
        .   
  has the same 
definition as    except that   
  is calculated based on the updated information.  
I simulate on each age group using the Double Exponential Jump Diffusion model 
for the life time. 
Table 11 Schedule of Benefits 
Form Description Initial 
Amount 
Benefit 
Period 
Ends 
Annual 
Premium 
Premiums 
Payable 
07000 Basic Plan $50,000 With Life $565.50 To 2047 
Table 12 Parts of Schedule of Insurance and Values 
Insurance Amount  Guaranteed Values 
End of Policy Year     Cash Value Dollars 
    
50,000 1996 Age 60 3,100.00 
50,000 1998 Age 62 4,038.50 
50,000 2001 Age 65 5,567.00 
50,000 2006 Age 70 8,438.50 
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Table 13 Adjusted and Standard Mortality Table for Age 70 with 2 Years Remaining Life 
Time 
Year 
 
 
 
 
  
Time 
 
 
 
 
   
Age 
 
 
 
 
  
Standard 
Table 
Rate 
 
 
   
Standard 
Table 
Probability 
 
 
   
Standard 
Table 
Survival 
Function 
 
   
Adjusted 
Table 
Rate 
 
 
  
 
 
Adjusted 
Table 
Probability 
 
 
   
Adjusted 
Table 
Survival 
Function 
 
  
  
2006 0 70 0.02539 0.02539 1.00000 0.30926 0.30926 1.00000 
2007 1 71 0.02664 0.02596 0.97461 0.30696 0.21203 0.69074 
2008 2 72 0.02796 0.02652 0.94865 0.30328 0.14518 0.47871 
2009 3 73 0.02934 0.02706 0.92213 0.29769 0.09929 0.33353 
2010 4 74 0.03084 0.02757 0.89507 0.28948 0.06781 0.23424 
2011 5 75 0.03233 0.02805 0.8675 0.27785 0.04624 0.16643 
2012 6 76 0.03394 0.02849 0.83945 0.26199 0.03149 0.12019 
2013 7 77 0.03563 0.0289 0.81096 0.24135 0.02141 0.08870 
2014 8 78 0.03741 0.02926 0.78206 0.21592 0.01453 0.06729 
2015 9 79 0.03928 0.02957 0.7528 0.18657 0.00984 0.05276 
2016 10 80 0.04125 0.02983 0.72323 0.15510 0.00666 0.04292 
2017 11 81 0.04385 0.03042 0.69343 0.12540 0.00455 0.03626 
2018 12 82 0.04663 0.03092 0.66299 0.09773 0.00310 0.03172 
2019 13 83 0.04962 0.03136 0.63208 0.07365 0.00211 0.02862 
2020 14 84 0.05282 0.03173 0.60072 0.05392 0.00143 0.02651 
2021 15 85 0.05625 0.03201 0.56899 0.03854 0.00097 0.02508 
2022 16 86 0.05995 0.03219 0.53698 0.02702 0.00065 0.02411 
2023 17 87 0.06391 0.03226 0.50479 0.01866 0.00044 0.02346 
2024 18 88 0.06817 0.03221 0.47253 0.01273 0.00029 0.02302 
2025 19 89 0.07275 0.03203 0.44032 0.00859 0.00020 0.02273 
2026 20 90 0.07768 0.03172 0.40828 0.00575 0.00013 0.02253 
2027 21 91 0.08298 0.03125 0.37657 0.00357 0.00008 0.02240 
2028 22 92 0.08869 0.03063 0.34532 0.00224 0.00005 0.02232 
2029 23 93 0.09485 0.02985 0.31469 0.00135 0.00003 0.02227 
2030 24 94 0.10147 0.02893 0.28484 0.00090 0.00002 0.02224 
2031 25 95 0.10862 0.02786 0.25594 0.00045 0.00001 0.02222 
2032 26 96 0.11633 0.02654 0.22814 0.00000 0.00000 0.00000 
2033 27 97 0.12465 0.02513 0.20162 0.00000 0.00000 0.00000 
2034 28 98 0.13363 0.02358 0.17647 0.00000 0.00000 0.00000 
2035 29 99 0.14333 0.02191 0.15289 0.00000 0.00000 0.00000 
2036 30 100 0.15381 0.02015 0.13097 0.00000 0.00000 0.00000 
2037 31 101 0.16515 0.01833 0.11083 0.00000 0.00000 0.00000 
2038 32 102 0.17746 0.01641 0.09253 0.00000 0.00000 0.00000 
2039 33 103 0.19067 0.01451 0.07611 0.00000 0.00000 0.00000 
2040 34 104 0.20503 0.01263 0.06169 0.00000 0.00000 0.00000 
2041 35 105 0.22058 0.01088 0.04897 0.00000 0.00000 0.00000 
2042 36 106 0.23743 0.00906 0.03817 0.00000 0.00000 0.00000 
2043 37 107 0.25571 0.00744 0.02911 0.00000 0.00000 0.00000 
2044 38 108 0.27552 0.00597 0.02166 0.00000 0.00000 0.00000 
2045 39 109 0.29703 0.00466 0.01569 0.00000 0.00000 0.00000 
2046 40 110 0.31926 0.00352 0.01103 0.00000 0.00000 0.00000 
2047 41 111 1.00000 0.00751 0.00751 0.00000 0.00000 0.00000 
Total    1.00000   1.00000  
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4.5 LIFE SETTLEMENT PRICING 
For life settlement pricing, we treat life settlements as zero-coupon bonds with 
random maturity whose Maturity is equal to the Life Expectancy ( ) of the individual 
whose policy is being settled. The Par Value is equal to the Net Death Benefit (NDB), 
whose Initial Price is equal to the Purchase Price (M), and where the Yield to Maturity is 
the same as that for a zero coupon bond of this character, as shown in Figure 13. 
Basic Definitions: 
     : Net death benefit (or face value) of the life policy 
      :  Premium for each year 
       :   Yield to maturity 
               :  Discount rate,   
 
   
   is the yield to maturity 
               :  Purchase Price for the life settlement 
           :  Random variable of life time 
Consider a hypothetical life settlement contract with a life expectancy of 4 years. 
Label this contract as contract  .  Assume that only 3 premium payments are made and 
the death benefit kicks in after the three premium payments, as shown in Figure 13. 
The relevant cash flows from buying this contract are: 
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Figure 13 The Cash Flow of the Life Settlement Contract 
                                                     B 
 
 
      M         P          P          P 
  
The formula for calculating the Purchase Pricing    is: 
          
    
  
   
          
 
      
 measures the present value of the net death benefit. This is the 
positive cash flow for the life settlement purchaser. 
         
    
  
   
 
      
   
    measures the present value of the premiums the purchaser 
has to continue to pay until the death of the policy holder. This is the negative cash flow 
for the life settlement purchaser. 
        is the purchase price at the date of purchasing.   
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Table 14 Life Settlement Prices for the Different Yield to Maturity 
Yield to Maturity 
  
Life Settlement Price 
  ($) 
5.00% 41190.75 
6.00% 40071.93 
7.00% 39010.62 
8.00% 38002.51 
9.00% 37043.73 
10.00% 36130.74 
11.00% 35260.35 
12.00% 34429.67 
13.00% 33636.03 
14.00% 32877.02 
15.00% 32150.44 
16.00% 31454.24 
17.00% 30786.58 
18.00% 30145.72 
Table 14 illustrates the third party purchase price for the different yields to maturity. The 
higher yield to maturity the third party requests, the lower the purchase price. But even 
the lowest purchase price $30,145.72 when the yield to maturity is 18% at the highest, is 
still higher than the cash value $8,438.50 in Table 12. This means the insured can gain 
more by selling the policy to the third party for the price of at least of $30,145.72 than to 
the insurance company at the surrender value $8,438.50. This is a win-win situation for 
both the insured and the third party (investor), which explains the potential huge profit 
and investment opportunity in the life settlement market. 
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Table 15 Life Settlement Price Sensitivity for different Yield to Maturity 
Yield to Maturity 
  
Life Settlement Price 
Sensitivity 
      
5.00% -111882 
6.00% -106131 
7.00% -100811 
8.00% -95878 
9.00% -91299 
10.00% -87039 
11.00% -83068 
12.00% -79364 
13.00% -75901 
14.00% -72658 
15.00% -69620 
16.00% -66766 
17.00% -64086 
18.00% N/A 
Table 15 illustrates the purchase price sensitivity for the different yield to 
maturity. There is a decreasing trend for the sensitivity. The sensitivity for the low yield 
is larger than that for the high yield.  
4.6 CONCLUSION 
In this paper, I investigate the methodology for pricing life settlement products. 
The life settlement products provide a way for a third party to purchase the life insurance 
policy for a price greater than the cash surrender value and less than the face value (or 
death benefit) in exchange for the right to collect the death benefit. Since the main 
element for pricing life settlement products is the estimation of the life expectancy of the 
insured, I adopt the Double Exponential Jump Diffusion (DEJD) model as the kernel for 
the projection of the mortality rate and the life expectancy. The DEJD model incorporates 
the longevity jump (caused by medical improvement,), the mortality jump (caused by 
pandemics) and the dynamic main trend of the mortality rate which provides better 
explanation and fit to the historical mortality rate data. Based on the DEJD model, I 
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propose a Whole Life Time Distribution Dynamic Pricing (WLTDDP) method to 
evaluate life settlement products. The method incorporates the updated information of life 
expectancy, a critical factor, into the evaluation of life settlement products. According to 
Jensen’s inequality, the value of the life settlement product is contingent on the expected 
value of the function of life time, which is always larger than the value of the function of 
the expected life time (or life expectancy). The WLTDDP method has the advantage of 
fixing the negative bias for pricing life settlement products in the previous method by 
generating the whole distribution for the life time instead of the solo life expectancy 
variable. The method incorporates more statistical information of the insured’s future life 
time. The statistical methodology is based upon information theory for adjusting 
mortality tables to obtain exactly some known individual characteristics while obtaining a 
table that is as close as possible to the standard one.  
I use an example of an insured who purchased a life insurance policy at age 40 in 
1986 and is age 70 in year 2006. The medical report shows the remaining expected life 
time is 2 years. The WLTDDP method generates the complete mortality table with the 
updated information of 2 years remaining life for the insured as illustrated in Table 13. 
Based on the complete life table, I can generate life settlement prices for different yields 
to maturity and the sensitivity. The results illustrate that the insured can gain more by 
selling the policy to a third party than to the insurance company at the surrender value. 
This is proof for the win-win situation for both the insured and the third party (investor) 
in the life settlement market. The results explain the potential huge profit and investment 
opportunity in the life settlement market. 
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